| #1 | Closed-loop transcranial focused ultrasound with 40Hz gamma entrainment to restore hippocampal-cortical connectivity in early MCI | PVALB | 1.000 | $0.96 | SDA-2026-04-03-26abc |
| #2 | Metabolic Reprogramming to Reverse Senescence | SIRT1,PGC1A,NAMPT | 1.000 | $0.98 | SDA-2026-04-04-gap-s |
| #3 | TREM2-Dependent Astrocyte-Microglia Cross-talk in Neurodegeneration | TREM2 | 0.990 | $0.87 | SDA-2026-04-03-gap-a |
| #4 | SASP Modulation Rather Than Cell Elimination | NFKB1,IL1B,BDNF | 0.981 | $0.97 | SDA-2026-04-04-gap-s |
| #5 | TREM2-Dependent Microglial Senescence Transition | TREM2 | 0.950 | $0.97 | SDA-2026-04-03-gap-a |
| #6 | Closed-loop transcranial focused ultrasound targeting EC-II SST interneurons to restore hippocampal gamma oscillations via upstream perforant path gating in Alzheimer's disease | SST | 0.948 | $0.96 | SDA-2026-04-03-26abc |
| #7 | Closed-loop optogenetic targeting PV interneurons to restore theta-gamma coupling and prevent amyloid-induced synaptic dysfunction in AD | PVALB | 0.944 | $0.82 | SDA-2026-04-03-26abc |
| #8 | PLCG2 Allosteric Modulation as a Precision Therapeutic for TREM2-Dependent Microglial Dysfunction | PLCG2 | 0.941 | $0.82 | SDA-2026-04-01-gap-0 |
| #9 | Plasma p-tau217-Triggered Exosome Dosing Maximizes lncRNA-0021 Therapeutic Window in AD | CSF p-tau217 (biomarker), lncRNA-0021, hUC-MSC exosomes | 0.938 | $0.87 | SDA-2026-04-16-gap-p |
| #10 | Multi-Biomarker Composite Index Surpassing Amyloid PET for Treatment Response Prediction | COMPOSITE_BIOMARKER | 0.933 | $0.86 | SDA-2026-04-16-gap-p |
| #11 | Closed-loop focused ultrasound targeting CA1 PV interneurons to restore theta-gamma coupling and block synaptotoxic Aβ oligomers in AD | PVALB | 0.927 | $0.85 | SDA-2026-04-03-26abc |
| #12 | Closed-loop transcranial focused ultrasound targeting EC-II SST interneurons to prevent tau propagation and restore entorhinal-hippocampal gamma synchrony in early Alzheimer's disease | SST | 0.922 | $0.85 | SDA-2026-04-03-26abc |
| #13 | CYP46A1 Gene Therapy for Age-Related TREM2-Mediated Microglial Senescence Reversal | CYP46A1 | 0.921 | $0.80 | SDA-2026-04-01-gap-l |
| #14 | Autophagy-Senescence Axis Therapeutic Window | ATG7,BCL2,BCL2L1 | 0.921 | $0.93 | SDA-2026-04-04-gap-s |
| #15 | Selective Acid Sphingomyelinase Modulation Therapy | SMPD1 | 0.920 | $0.80 | SDA-2026-04-01-gap-l |
| #16 | HK2-Dependent Metabolic Checkpoint as the Gatekeeper of DAM Transition | HK2 | 0.919 | $0.91 | SDA-2026-04-16-gap-d |
| #17 | Palmitoylethanolamide-Based Endocannabinoid Therapy | PPARA | 0.919 | $0.80 | SDA-2026-04-16-gap-b |
| #18 | CYP46A1 Overexpression Gene Therapy | CYP46A1 | 0.919 | $0.92 | SDA-2026-04-01-gap-l |
| #19 | Closed-loop transcranial focused ultrasound to restore hippocampal gamma oscillations via cholecystokinin interneuron neuromodulation in Alzheimer's disease | CCK | 0.912 | $0.87 | SDA-2026-04-03-26abc |
| #20 | SASP-Mediated Complement Cascade Amplification | C1Q/C3 | 0.910 | $0.93 | sda-2026-04-01-gap-0 |
| #21 | TREM2-Mediated Astrocyte-Microglia Cross-Talk in Neurodegeneration | TREM2 | 0.907 | $0.81 | SDA-2026-04-03-gap-a |
| #22 | Nutrient-Sensing Epigenetic Circuit Reactivation | SIRT1 | 0.907 | $0.83 | SDA-2026-04-04-gap-e |
| #23 | Closed-loop focused ultrasound targeting EC-II SST interneurons to restore gamma gating and block tau propagation in AD | SST | 0.900 | $0.95 | SDA-2026-04-03-26abc |
| #24 | Closed-loop tACS targeting EC-II SST interneurons to block tau propagation and restore perforant-path gamma gating in AD | SST | 0.896 | $0.78 | SDA-2026-04-03-26abc |
| #25 | SIRT1-Mediated Reversal of TREM2-Dependent Microglial Senescence | SIRT1 | 0.895 | $0.83 | SDA-2026-04-03-gap-a |
| #26 | Gut Microbiome Remodeling to Prevent Systemic NLRP3 Priming in Neurodegeneration | NLRP3, CASP1, IL1B, PYCARD | 0.888 | $0.91 | SDA-2026-04-01-gap-2 |
| #27 | Multi-Target Hypothesis: Aβ-Induced Cholinergic Damage is Partially Irreversible | APP/PSEN1 (Aβ production), CHAT (cholinergic synthesis) | 0.887 | $0.81 | SDA-2026-04-12-20260 |
| #28 | H1: TREM2 Agonism to Redirect APOE4-Enhanced Microglia from Synapse Pruning to Amyloid Clearance | TREM2 | 0.887 | $0.90 | SDA-2026-04-12-gap-p |
| #29 | Focused Ultrasound with Microbubble Contrast Agents for Antibody CNS Delivery | CLDN5/ZO-1 tight junction complex; KDR/VEGFR2 | 0.886 | $0.89 | SDA-2026-04-02-gap-b |
| #30 | TREM2-APOE Axis Dissociation for Selective DAM Activation | TREM2-APOE axis | 0.886 | $0.86 | SDA-2026-04-01-gap-0 |
| #31 | Transcriptional Autophagy-Lysosome Coupling | FOXO1 | 0.882 | $0.90 | sda-2026-04-01-gap-0 |
| #32 | TREM2-Mediated Astrocyte-Microglia Cross-Talk in Neurodegeneration | TREM2 | 0.880 | $0.92 | SDA-2026-04-03-gap-a |
| #33 | TREM2-Mediated Astrocyte-Microglia Cross-Talk in Neurodegeneration | TREM2 | 0.875 | $0.92 | SDA-2026-04-03-gap-a |
| #34 | TREM2-Mediated Cholesterol Dysregulation in Microglial Senescence | CYP46A1 | 0.869 | $0.89 | SDA-2026-04-03-gap-a |
| #35 | GluN2B-Mediated Thalamocortical Control of Glymphatic Tau Clearance | GRIN2B | 0.869 | $0.75 | SDA-2026-04-03-26abc |
| #36 | Complement Cascade Inhibition Synaptic Protection | - | 0.867 | $0.81 | SDA-2026-04-16-gap-p |
| #37 | Closed-loop tACS targeting EC-II PV interneurons to enhance perisomatic inhibition and block tau propagation in AD | PVALB | 0.867 | $0.81 | SDA-2026-04-03-26abc |
| #38 | Optogenetic restoration of hippocampal gamma oscillations via selective PV interneuron activation using implantable LED arrays in Alzheimer's disease | PVALB | 0.863 | $0.81 | SDA-2026-04-03-26abc |
| #39 | Closed-loop focused ultrasound targeting EC-II PV interneurons to restore theta-gamma coupling and prevent tau seeding in AD | PVALB | 0.863 | $0.88 | SDA-2026-04-03-26abc |
| #40 | Hippocampal CA3-CA1 synaptic rescue via DHHC2-mediated PSD95 palmitoylation stabilization | BDNF | 0.861 | $0.81 | SDA-2026-04-03-26abc |
| #41 | Closed-loop transcranial focused ultrasound to restore hippocampal gamma oscillations via direct PV interneuron recruitment in Alzheimer's disease | PVALB | 0.858 | $0.98 | SDA-2026-04-03-26abc |
| #42 | TREM2 R47H Variant-Driven Metabolic Dysfunction as the Primary Trigger for Failed DAM Transition | NAMPT | 0.858 | $0.74 | SDA-2026-04-16-gap-d |
| #43 | Closed-loop tACS targeting EC-II PV interneurons to suppress burst firing and block tau propagation via perforant path in AD | PVALB | 0.857 | $0.92 | SDA-2026-04-03-26abc |
| #44 | Senescent Cell ASM-Complement Cascade Intervention | SMPD1 | 0.852 | $0.87 | SDA-2026-04-01-gap-l |
| #45 | Gamma entrainment therapy to restore hippocampal-cortical synchrony | SST | 0.851 | $0.79 | SDA-2026-04-03-26abc |
| #46 | APOE-Dependent Autophagy Restoration | MTOR | 0.850 | $0.78 | sda-2026-04-01-gap-a |
| #47 | Microglial Senescence Prevention via TREM2/SASP Axis | - | 0.847 | $0.78 | SDA-2026-04-16-gap-p |
| #48 | ACSL4-Driven Ferroptotic Priming in Disease-Associated Microglia | ACSL4 | 0.847 | $0.86 | SDA-2026-04-03-gap-s |
| #49 | Optogenetic viral vector delivery via tFUS-mediated blood-brain barrier opening to restore hippocampal gamma oscillations through PV interneuron activation in Alzheimer's disease | PVALB | 0.846 | $0.87 | SDA-2026-04-03-26abc |
| #50 | Optogenetic restoration of hippocampal gamma oscillations via selective SST interneuron activation targeting dendritic inhibition in Alzheimer's disease | SST | 0.845 | $0.87 | SDA-2026-04-03-26abc |
| #51 | Neutral Sphingomyelinase-2 Inhibition for Synaptic Protection in Neurodegeneration | SMPD3 | 0.844 | $0.87 | SDA-2026-04-01-gap-l |
| #52 | TYROBP (DAP12) Conditional Antagonism for Early-Stage Neuroprotection | TYROBP | 0.844 | $0.72 | SDA-2026-04-01-gap-0 |
| #53 | miR-155/Interferon-gamma Feedback Loop as a Reversible Molecular Switch for Protective Microglial State Transition | MIR155 | 0.843 | $0.82 | SDA-2026-04-16-gap-d |
| #54 | Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation | HCRTR1/HCRTR2 | 0.841 | $0.86 | sda-2026-04-01-gap-v |
| #55 | Hypothesis 7: SST-SST1R/Gamma Entrainment-Enhanced Astrocyte Secretome | SST, SSTR1, SSTR2 | 0.839 | $0.92 | SDA-2026-04-16-gap-p |
| #56 | Gamma Oscillation Enhancement Synergy | - | 0.838 | $0.82 | SDA-2026-04-16-gap-p |
| #57 | Sequential Iron Chelation (Deferoxamine) and GPX4 Restoration (Sulforaphane) Prevents the Self-Amplifying Iron-Ferroptosis-Edema Cascade Post-Cardiac Arrest | Labile iron pool (deferoxamine target) and GPX4 (sulforaphane target) | 0.838 | $0.78 | SDA-2026-04-16-gap-p |
| #58 | H6: Aberrant eIF2α Phosphorylation Creates Stalled Translation State | EIF2S1, EIF2AK3/PERK, PPP1R15B, EIF2B | 0.834 | $0.71 | SDA-2026-04-06-gap-p |
| #59 | Closed-loop tACS targeting EC-II parvalbumin interneurons to restore gamma rhythmogenesis and block tau AIS disruption in AD | PVALB | 0.831 | $0.93 | SDA-2026-04-03-26abc |
| #60 | Closed-loop transcranial focused ultrasound to restore hippocampal gamma oscillations via glymphatic enhancement and amyloid clearance from PV interneurons in Alzheimer's disease | PVALB | 0.827 | $0.76 | SDA-2026-04-03-26abc |
| #61 | Real-time gamma-guided transcranial focused ultrasound targeting EC-II SST interneurons to restore hippocampal-prefrontal synchrony in early AD | SST | 0.827 | $0.78 | SDA-2026-04-03-26abc |
| #62 | Beta-frequency entrainment therapy targeting PV interneuron-astrocyte coupling for tau clearance | SST | 0.827 | $0.89 | SDA-2026-04-03-26abc |
| #63 | Microglial AIM2 Inflammasome as the Primary Driver of TDP-43 Proteinopathy Neuroinflammation in ALS/FTD | AIM2, CASP1, IL1B, PYCARD, TARDBP | 0.824 | $0.86 | SDA-2026-04-01-gap-2 |
| #64 | Astrocyte-Intrinsic NLRP3 Inflammasome Activation by Alpha-Synuclein Aggregates Drives Non-Cell-Autonomous Neurodegeneration | NLRP3, CASP1, IL1B, PYCARD | 0.822 | $0.72 | SDA-2026-04-01-gap-2 |
| #65 | Glymphatic-Mediated Tau Clearance Dysfunction | MAPT | 0.821 | $0.85 | SDA-2026-04-03-26abc |
| #66 | Hippocampal CA3-CA1 circuit rescue via neurogenesis and synaptic preservation | BDNF | 0.820 | $0.70 | SDA-2026-04-03-26abc |
| #67 | Ketone Utilization Index as Metabolic Flexibility Biomarker | HMGCS2 | 0.819 | $0.83 | SDA-2026-04-04-gap-d |
| #68 | Extracellular Vesicle Biogenesis Modulation | CHMP4B | 0.814 | $0.73 | SDA-2026-04-04-gap-t |
| #69 | AMPK hypersensitivity in astrocytes creates enhanced mitochondrial rescue responses | PRKAA1 | 0.813 | $0.69 | sda-2026-04-01-gap-v |
| #70 | TREM2-Mediated Microglial Dysfunction Disrupts Perivascular Tau Clearance | TREM2 | 0.812 | $0.86 | SDA-2026-04-03-26abc |
| #71 | CLU/APOE Duality in Amyloid Clearance Determines Cell-Type-Specific Vulnerability Thresholds | APOE, CLU | 0.811 | $0.69 | SDA-2026-04-15-gap-d |
| #72 | LRP1-Dependent Tau Uptake Disruption | LRP1 | 0.808 | $0.77 | SDA-2026-04-04-gap-t |
| #73 | CSF1R-TREM2 Co-Agonism for Sustained Microglial Expansion | CSF1R-TREM2 | 0.808 | $0.78 | SDA-2026-04-01-gap-0 |
| #74 | P2RX7-Mediated Exosome Secretion Blockade | P2RX7 | 0.807 | $0.78 | SDA-2026-04-04-gap-t |
| #75 | Neutrophil Extracellular Trap (NET) Inhibition | PADI4 | 0.806 | $0.74 | SDA-2026-04-16-gap-b |
| #76 | Mitochondrial DAMPs-Driven AIM2 Inflammasome Activation in Neurodegeneration | AIM2, CASP1, IL1B, PYCARD | 0.805 | $0.78 | SDA-2026-04-01-gap-2 |
| #77 | Calcium-Dysregulated mPTP Opening as an Alternative mtDNA Release Mechanism for AIM2 Inflammasome Activation in Neurodegeneration | AIM2, CASP1, IL1B, PYCARD, PPIF | 0.804 | $0.77 | SDA-2026-04-01-gap-2 |
| #78 | TREM2-mTOR Co-Agonism for Metabolic Reprogramming | TREM2-mTOR pathway | 0.803 | $0.74 | SDA-2026-04-01-gap-0 |
| #79 | Dual-Receptor Antibody Shuttling | - | 0.803 | $0.87 | - |
| #80 | Prime Editing Precision Correction of APOE4 to APOE3 in Microglia | APOE | 0.803 | $0.68 | SDA-2026-04-03-gap-c |
| #81 | Mitochondrial DNA-Driven AIM2 Inflammasome Activation in Neurodegeneration | AIM2, CASP1, IL1B, PYCARD | 0.803 | $0.68 | SDA-2026-04-01-gap-2 |
| #82 | 40 Hz Gamma Entrainment Gates ACSL4-Mediated Ferroptotic Priming to Selectively Eliminate Disease-Associated Microglia | ACSL4 | 0.801 | $0.76 | SDA-2026-04-03-gap-s |
| #83 | ACSL4-Ferroptotic Priming in Stressed Oligodendrocytes Drives White Matter Degeneration in Alzheimer's Disease | ACSL4 | 0.801 | $0.71 | SDA-2026-04-03-gap-s |
| #84 | TREM2 Deficiency Drives Microglial Senescence via Lipid Metabolism Dysregulation | TREM2/TYROBP | 0.800 | $0.72 | SDA-2026-04-06-gap-p |
| #85 | Microglial TREM2-SYK Pathway Enhancement | TREM2 | 0.798 | $0.74 | SDA-2026-04-03-gap-s |
| #86 | Closed-loop transcranial focused ultrasound targeting CA1 PV interneurons with real-time gamma feedback to prevent tau propagation and restore hippocampal-prefrontal synchrony in Alzheimer's disease | PVALB | 0.797 | $0.82 | SDA-2026-04-03-26abc |
| #87 | SASP-Driven Microglial Metabolic Reprogramming in Synaptic Phagocytosis | HK2/PFKFB3 | 0.796 | $0.94 | sda-2026-04-01-gap-0 |
| #88 | Selective APOE4 Degradation via Proteolysis Targeting Chimeras (PROTACs) | APOE | 0.795 | $0.75 | sda-2026-04-01-gap-0 |
| #89 | Microglial-Mediated Tau Clearance Dysfunction via TREM2 Signaling | TREM2 | 0.792 | $0.82 | SDA-2026-04-03-26abc |
| #90 | CYP46A1 Suppression for Tau-Mediated Neurodegeneration | CYP46A1 | 0.792 | $0.82 | SDA-2026-04-01-gap-l |
| #91 | Excitatory Neuron Synaptic Dysfunction and Mitochondrial Stress via MAPT (tau) | MAPT | 0.790 | $0.79 | SDA-2026-04-02-gap-s |
| #92 | Selective TLR4 Modulation to Prevent Gut-Derived Neuroinflammatory Priming | TLR4 | 0.789 | $0.81 | SDA-2026-04-01-gap-2 |
| #93 | VCP-Mediated Autophagy Enhancement | VCP | 0.787 | $0.67 | SDA-2026-04-04-gap-t |
| #94 | Closed-loop transcranial alternating current stimulation to restore hippocampal-prefrontal gamma synchrony via PV interneuron rescue | SST | 0.785 | $0.86 | SDA-2026-04-03-26abc |
| #95 | Vicious Cycle Hypothesis: Cholinergic Dysfunction Exacerbates Amyloid Pathology | CHRNA7 (α7 nicotinic receptor), BACE1 | 0.785 | $0.81 | SDA-2026-04-12-20260 |
| #96 | Competitive APOE4 Domain Stabilization Peptides | APOE | 0.784 | $0.80 | sda-2026-04-01-gap-0 |
| #97 | Senescent Microglia Resolution via Maresins-Senolytics Combination | BCL2L1 | 0.784 | $0.66 | sda-2026-04-01-gap-0 |
| #98 | Closed-loop tACS targeting entorhinal cortex layer II SST interneurons to activate AMPK-autophagy flux and degrade intracellular tau before exosomal packaging in Alzheimer's disease | SST | 0.784 | $0.87 | SDA-2026-04-03-26abc |
| #99 | SASP-Driven Aquaporin-4 Dysregulation | AQP4 | 0.782 | $0.80 | sda-2026-04-01-gap-0 |
| #100 | TREM2-mediated microglial tau clearance enhancement | TREM2 | 0.780 | $0.67 | SDA-2026-04-04-gap-t |
| #101 | Sleep-Dependent Glymphatic Clearance Expands the Therapeutic Window by Reducing Extracellular Tau Burden | AQP4, orexin receptor (HCRTR1/2) | 0.780 | $0.78 | SDA-2026-04-06-gap-d |
| #102 | LPCAT3-Mediated Lands Cycle Remodeling as the Primary Ferroptotic Priming Engine in Disease-Associated Microglia | LPCAT3 | 0.779 | $0.82 | SDA-2026-04-03-gap-s |
| #103 | ACSL4-Driven Ferroptotic Priming in Disease-Associated Oligodendrocytes Underlies White Matter Degeneration in Alzheimer's Disease | ACSL4 | 0.779 | $0.82 | SDA-2026-04-03-gap-s |
| #104 | Selective HDAC3 Inhibition with Cognitive Enhancement | HDAC3 | 0.779 | $0.80 | SDA-2026-04-04-gap-e |
| #105 | APOE4-Specific Proteolytic Fragment Inhibition Therapy | APOE | 0.777 | $0.76 | - |
| #106 | ALOX15-Driven Enzymatic Ferroptosis in AD Oligodendrocytes via PUFA-PE Peroxidation | ALOX15 | 0.777 | $0.82 | SDA-2026-04-03-gap-s |
| #107 | LPCAT3-Mediated Lands Cycle Amplification of Ferroptotic Substrate Pools in Disease-Associated Microglia | LPCAT3 | 0.776 | $0.67 | SDA-2026-04-03-gap-s |
| #108 | Prefrontal sensory gating circuit restoration via PV interneuron enhancement | PVALB | 0.775 | $0.79 | SDA-2026-04-03-26abc |
| #109 | Alpha-gamma cross-frequency coupling enhancement to restore thalamo-cortical memory circuits | SST | 0.775 | $0.94 | SDA-2026-04-03-26abc |
| #110 | Dual-Domain Antibodies with Engineered Fc-FcRn Affinity Modulation | FCGRT | 0.773 | $0.79 | sda-2026-04-01-gap-0 |
| #111 | LPCAT3-Mediated Lands Cycle Amplification of Ferroptotic Vulnerability in Disease-Associated Microglia | LPCAT3 | 0.770 | $0.66 | SDA-2026-04-03-gap-s |
| #112 | Direct Toxicity Hypothesis: β-Amyloid Directly Impairs Cholinergic Signaling | CHRNA7, CHRM1 | 0.769 | $0.72 | SDA-2026-04-12-20260 |
| #113 | Chromatin Accessibility Restoration via BRD4 Modulation | BRD4 | 0.768 | $0.79 | SDA-2026-04-04-gap-e |
| #114 | Lysosomal Cathepsin-Dependent Tau Clearance | - | 0.767 | $0.75 | SDA-2026-04-16-gap-p |
| #115 | Closed-loop transcranial focused ultrasound to restore hippocampal gamma oscillations via somatostatin interneuron disinhibition in Alzheimer's disease | SST | 0.767 | $0.94 | SDA-2026-04-03-26abc |
| #116 | HDL/apoE Particle Remodeling as a Therapeutic Switch for CAA Prevention | ABCA1 | 0.766 | $0.75 | SDA-2026-04-15-gap-p |
| #117 | APOE4 Allosteric Rescue via Small Molecule Chaperones | APOE | 0.765 | $0.79 | sda-2026-04-01-gap-0 |
| #118 | SASP-Mediated Cholinergic Synapse Disruption | MMP2/MMP9 | 0.763 | $0.78 | sda-2026-04-01-gap-0 |
| #119 | Circadian Clock-Autophagy Synchronization | CLOCK | 0.763 | $0.78 | sda-2026-04-01-gap-v |
| #120 | Cell-Type Specific TREM2 Upregulation in DAM Microglia | TREM2 | 0.761 | $0.78 | analysis-SEAAD-20260 |
| #121 | cGAS-STING Pathway Hyperactivation Mediates Tau Propagation | cGAS (CGAS), STING (TMEM173) | 0.760 | $0.76 | SDA-2026-04-02-gap-2 |
| #122 | APOE4 astrocytes exhibit impaired cholesterol efflux via ABCA1/ABCG1 transporters, driving intracellular lipid droplet accumulation and secondary neuronal cholesterol deficiency | ABCA1, ABCG1 | 0.760 | $0.76 | SDA-2026-04-04-gap-a |
| #123 | Targeted APOE4-to-APOE3 Base Editing Therapy | APOE | 0.758 | $0.78 | sda-2026-04-01-gap-0 |
| #124 | INPP5D (SHIP1) Inhibition to Shift Microglial Polarization | INPP5D | 0.758 | $0.74 | SDA-2026-04-01-gap-0 |
| #125 | sTREM2 as Biomarker of Cystatin-C Therapeutic Efficacy | - | 0.757 | $0.87 | SDA-2026-04-16-gap-p |
| #126 | Multi-Modal Stress Response Harmonization | NR3C1/CRH/TNFA | 0.756 | $0.77 | sda-2026-04-01-gap-0 |
| #127 | Senescence-Activated NAD+ Depletion Rescue | CD38/NAMPT | 0.755 | $0.77 | sda-2026-04-01-gap-0 |
| #128 | Test: TREM2 enhances amyloid clearance | - | 0.755 | $0.70 | - |
| #129 | Dual-Circuit Tau Vulnerability Cascade | MAPT | 0.754 | $0.70 | SDA-2026-04-03-26abc |
| #130 | GFAP-Positive Reactive Astrocyte Subtype Delineation | GFAP | 0.754 | $0.77 | analysis-SEAAD-20260 |
| #131 | Enhancing Microglial Phagocytosis of Extracellular Tau via TREM2 Activation | TREM2 | 0.750 | $0.75 | SDA-2026-04-04-gap-t |
| #132 | TREM2-CSF1R Cross-Talk in Microglial Metabolic Reprogramming | TREM2, CSF1R | 0.748 | $0.90 | SDA-2026-04-03-gap-a |
| #133 | C1QA/C1QB Subunit-Specific Inhibition to Block Aberrant PV Interneuron Input Elimination in Alzheimer's Disease | C1QA, C1QB | 0.747 | $0.70 | SDA-2026-04-15-gap-d |
| #134 | Circadian-Synchronized Proteostasis Enhancement | CLOCK/ULK1 | 0.744 | $0.76 | sda-2026-04-01-gap-0 |
| #135 | APOE Isoform Expression Across Glial Subtypes | APOE | 0.743 | $0.69 | analysis-SEAAD-20260 |
| #136 | BACE1/NRG1 Axis Dysfunction Drives Excitatory/Inhibitory Imbalance via PV Interneuron Hypofunction | NRG1/ERBB4 | 0.743 | $0.73 | SDA-2026-04-15-gap-p |
| #137 | Senescent Cell Mitochondrial DNA Release | CGAS/STING1/DNASE2 | 0.742 | $0.76 | sda-2026-04-01-gap-0 |
| #138 | Near-infrared light therapy stimulates COX4-dependent mitochondrial motility enhancement | COX4I1 | 0.742 | $0.76 | sda-2026-04-01-gap-v |
| #139 | Cholinergic Basal Forebrain-Hippocampal Circuit Protection | MAPT | 0.742 | $0.75 | SDA-2026-04-03-26abc |
| #140 | APOE4-Selective Lipid Nanoemulsion Therapy | APOE | 0.742 | $0.77 | sda-2026-04-01-gap-a |
| #141 | APOE-TREM2 Interaction Modulation | TREM2 | 0.741 | $0.76 | sda-2026-04-01-gap-a |
| #142 | miR-33 Antisense Oligonucleotide Hyper-Lipidation Strategy | miR-33/ABCA1 | 0.741 | $0.69 | SDA-2026-04-16-gap-d |
| #143 | Complement-SASP Amplification Cascade as Mechanistic Link | C1QA, C1QB, C3, IL1B, NFKB1 | 0.741 | $0.69 | SDA-2026-04-16-gap-p |
| #144 | Epigenetic Memory Erasure via TET2 Activation | TET2 | 0.741 | $0.76 | sda-2026-04-01-gap-0 |
| #145 | TREM2-APOE4 Co-targeting — Simultaneous Correction of Lipid Sensing and Clearance Deficits | TREM2, APOE | 0.741 | $0.62 | SDA-2026-04-02-gap-0 |
| #146 | VPS35 retromer activation prevents endosomal tau templating across all brain regions and disease stages | VPS35 | 0.740 | $0.74 | SDA-2026-04-07-gap-d |
| #147 | Exposed amyloidogenic segments (β-sheet propensity residues) serve as HSP70 recognition codes | HSPA8, HSPA1A, DNAJB6, DNAJB2 | 0.740 | $0.66 | SDA-2026-04-10-gap-d |
| #148 | Inhibiting Heparan Sulfate Proteoglycan Receptor-Mediated Neuronal Tau Uptake | SULF1/SULF2 | 0.740 | $0.74 | SDA-2026-04-04-gap-t |
| #149 | Dopaminergic Ventral Tegmental-Hippocampal Circuit Protection | MAPT | 0.740 | $0.75 | SDA-2026-04-03-26abc |
| #150 | PARP1 Inhibition Therapy | PARP1 | 0.738 | $0.76 | sda-2026-04-01-gap-0 |
| #151 | SIRT3-Mediated Mitochondrial Deacetylation Failure with PINK1/Parkin Mitophagy Dysfunction | SIRT3 | 0.738 | $0.76 | SDA-2026-04-03-gap-s |
| #152 | Microglial-Mediated Tau Clearance Dysfunction via TREM2 Receptor Impairment | MAPT | 0.737 | $0.76 | SDA-2026-04-03-26abc |
| #153 | Stage-Specific TREM2 Biomarker-Guided Switching — Agonist in Amyloid Phase, Antagonist in Tau Phase | TREM2, APOE, MAPT | 0.735 | $0.72 | SDA-2026-04-02-gap-0 |
| #154 | TREM2 Agonism to Restore Microglial Phagocytosis Across Both Pathologies | TREM2, TYROBP (DAP12), PLCG2, SYK | 0.735 | $0.68 | SDA-2026-04-16-gap-p |
| #155 | Metabolic Inflexibility Precedes Transcriptional Reprogramming (NAD+/SIRT3 Axis) | SIRT3/NAD+ salvage pathway, PGC-1α | 0.735 | $0.65 | SDA-2026-04-06-gap-d |
| #156 | SGMS1-Driven Sphingomyelin Accumulation Impairs BACE1 Lysosomal Degradation via Autophagosome-Lysosome Fusion Dysfunction | SGMS1, BECN1 | 0.734 | $0.72 | SDA-2026-04-15-gap-p |
| #157 | Aquaporin-4 Polarization Rescue | AQP4 | 0.732 | $0.76 | sda-2026-04-01-gap-0 |
| #158 | Senescence-Associated Myelin Lipid Remodeling | PLA2G6/PLA2G4A | 0.732 | $0.75 | sda-2026-04-01-gap-0 |
| #159 | Selective Neutral Sphingomyelinase-2 Inhibition Therapy | SMPD3 | 0.731 | $0.85 | SDA-2026-04-01-gap-l |
| #160 | Senescence-Induced Lipid Peroxidation Spreading | GPX4/SLC7A11 | 0.730 | $0.68 | sda-2026-04-01-gap-0 |
| #161 | H1: T-Type Calcium Channel–Driven Calcium Overload and Proteostasis Collapse | CACNA1H (Cav3.2), CAPN2, PPP2R2D | 0.730 | $0.73 | SDA-2026-04-02-gap-e |
| #162 | Adenosine-Astrocyte Metabolic Reset | ADORA2A | 0.730 | $0.75 | sda-2026-04-01-gap-v |
| #163 | Phase-Separated Organelle Targeting | G3BP1 | 0.729 | $0.75 | sda-2026-04-01-gap-0 |
| #164 | Temporal SPP1 Inhibition During Critical Windows | SPP1 | 0.728 | $0.76 | SDA-2026-04-15-gap-p |
| #165 | Thalamocortical Synchrony Restoration via NMDA Modulation | GRIN2B | 0.728 | $0.74 | SDA-2026-04-03-26abc |
| #166 | Synthetic Biology BBB Endothelial Cell Reprogramming | TFR1, LRP1, CAV1, ABCB1 | 0.727 | $0.75 | sda-2026-04-01-gap-0 |
| #167 | Metabolic Switch Targeting for A1→A2 Repolarization | HK2 | 0.726 | $0.75 | sda-2026-04-01-gap-0 |
| #168 | Microglial TREM2-Complement Axis Modulation | TREM2 and C3 | 0.726 | $0.75 | SDA-2026-04-03-gap-s |
| #169 | TFAM overexpression creates mitochondrial donor-recipient gradients for directed organelle trafficking | TFAM | 0.725 | $0.75 | sda-2026-04-01-gap-v |
| #170 | Astrocyte-Mediated Neuronal Epigenetic Rescue | HDAC | 0.725 | $0.68 | SDA-2026-04-04-gap-e |
| #171 | Proteostasis Enhancement via APOE Chaperone Targeting | HSPA1A | 0.724 | $0.75 | sda-2026-04-01-gap-a |
| #172 | Microbial Inflammasome Priming Prevention | NLRP3, CASP1, IL1B, PYCARD | 0.723 | $0.74 | SDA-2026-04-01-gap-2 |
| #173 | Interfacial Lipid Mimetics to Disrupt Domain Interaction | APOE | 0.723 | $0.75 | sda-2026-04-01-gap-0 |
| #174 | Circadian Rhythm Entrainment of Reactive Astrocytes | BMAL1 | 0.722 | $0.75 | sda-2026-04-01-gap-0 |
| #175 | Sleep Spindle-Synaptic Plasticity Enhancement | CACNA1G | 0.721 | $0.75 | sda-2026-04-01-gap-v |
| #176 | LXRβ-Selective Agonism as a Precision Therapeutic for APOE4-Driven Myelin Deficits | NR1H2 (LXRβ) | 0.721 | $0.70 | SDA-2026-04-14-gap-p |
| #177 | Astroglial Gap Junction Coordination via Connexin-43 Phosphorylation Modulation | GJA1 | 0.720 | $0.75 | sda-2026-04-01-gap-v |
| #178 | H3: APOE4 Impairs Cholesterol Trafficking, Triggering Astrocyte Senescence | ABCA1/ABCG1; LXR (NR1H3) | 0.720 | $0.72 | SDA-2026-04-06-gap-d |
| #179 | NLRP3 Inflammasome Lock Perpetuates Senescence-Associated Inflammasome Phenotype | NLRP3/CASP1/IL1B | 0.720 | $0.72 | SDA-2026-04-06-gap-p |
| #180 | Bacterial Curli Amyloid → Nucleation of α-Synuclein Misfolding in Enteric Neurons | CsgA, CsgB, CsgC, α-synuclein (SNCA) | 0.720 | $0.72 | sda-2026-04-01-gap-2 |
| #181 | Excessive C1q/C3/CR3 complement cascade activation initiates pre-symptomatic synaptic loss in Alzheimer's disease | C1QA, C1QB, C1QC, C3, ITGAM/ITGAX | 0.720 | $0.72 | SDA-2026-04-02-gap-s |
| #182 | Antisense Oligonucleotide-Mediated APOE4 Haploinsufficiency | APOE | 0.720 | $0.72 | SDA-2026-04-02-gap-a |
| #183 | Stress Granule Phase Separation Modulators | G3BP1 | 0.720 | $0.67 | sda-2026-04-01-gap-v |
| #184 | Magnetosonic-Triggered Transferrin Receptor Clustering | TFR1 | 0.719 | $0.75 | sda-2026-04-01-gap-0 |
| #185 | Retinal Vascular Microcirculation Rescue | PDGFRB/ANGPT1 | 0.718 | $0.74 | sda-2026-04-01-gap-0 |
| #186 | TREM2-DAP12 Signalosome Enhancement — Boosting PI3K-AKT-mTOR Axis for Microglial Metabolic Fitness | TREM2, TYROBP, SYK, PI3K | 0.718 | $0.70 | SDA-2026-04-02-gap-0 |
| #187 | Disease-Associated Microglia Metabolic Reprogramming | TREM2 | 0.718 | $0.67 | SDA-2026-04-03-gap-s |
| #188 | APOE Isoform Conversion Therapy | APOE | 0.718 | $0.75 | sda-2026-04-01-gap-a |
| #189 | Engineered Apolipoprotein E4-Neutralizing Shuttle Peptides | APOE, LRP1, LDLR | 0.718 | $0.74 | sda-2026-04-01-gap-0 |
| #190 | Vascular-Glial Interface Restoration | CLDN5 | 0.716 | $0.74 | SDA-2026-04-03-gap-s |
| #191 | Circadian-Synchronized LRP1 Pathway Activation | LRP1, MTNR1A, MTNR1B | 0.714 | $0.74 | sda-2026-04-01-gap-0 |
| #192 | Soluble TREM2 (sTREM2) as Therapeutic Mimic — Decoupling Phagocytosis from Inflammation | TREM2, ADAM10, ADAM17 | 0.714 | $0.70 | SDA-2026-04-02-gap-0 |
| #193 | Purinergic Signaling Polarization Control | P2RY1 and P2RX7 | 0.713 | $0.73 | sda-2026-04-01-gap-0 |
| #194 | Test: TREM2 enhances amyloid clearance | - | 0.712 | $0.70 | - |
| #195 | Circadian Glymphatic Rescue Therapy (Melatonin-focused) | MTNR1A | 0.712 | $0.74 | sda-2026-04-01-gap-v |
| #196 | Early Proteasome Restoration Therapy | PSMC | 0.712 | $0.66 | SDA-2026-04-03-gap-a |
| #197 | Noradrenergic-Tau Propagation Blockade | ADRA2A | 0.711 | $0.74 | sda-2026-04-01-gap-v |
| #198 | APOE4-Specific Microglial Metabolic Rescue | APOE, ABCA1, LDLR | 0.710 | $0.74 | SDA-2026-04-04-gap-n |
| #199 | HDAC3-Selective Inhibition for Clock Reset | HDAC3 | 0.710 | $0.74 | sda-2026-04-01-gap-v |
| #200 | Conformational-Selective Blocking of Tau Uptake Reveals Therapeutic Window in Neuronal Re-entry | LRP1, HSPG (SDC3, GPC1), tau conformations | 0.710 | $0.71 | SDA-2026-04-06-gap-d |
| #201 | Microglial Disease-Associated States: TREM2-Independent Pathways Driving Neuroinflammation | APOE | 0.710 | $0.71 | SDA-2026-04-02-gap-s |
| #202 | Regional TREM2-Dependent Lipid Metabolism Determines Cortical Vulnerability in Alzheimer's Disease | TREM2 | 0.710 | $0.71 | SDA-2026-04-06-gap-p |
| #203 | H4: Senomorphic Compounds Preserve Astrocyte Function While Reversing Senescence | MTOR; MEGF10; MERTK | 0.710 | $0.71 | SDA-2026-04-06-gap-d |
| #204 | CSF YKL-40 as a Priming-Specific Chitinase Marker | CHI3L1/YKL-40 | 0.710 | $0.71 | SDA-2026-04-06-gap-d |
| #205 | Selective LXRβ agonists restore ABCA1/ABCG1 expression and APOE lipidation in APOE4 astrocytes, normalizing cholesterol export and reducing AD-relevant neurotoxicity | NR1H2 (LXRβ), ABCA1, ABCG1 | 0.710 | $0.71 | SDA-2026-04-04-gap-a |
| #206 | Metabolic Circuit Breaker via Lipid Droplet Modulation | PLIN2 | 0.709 | $0.74 | sda-2026-04-01-gap-0 |
| #207 | Autophagosome Maturation Checkpoint Control | STX17 | 0.709 | $0.74 | sda-2026-04-01-gap-0 |
| #208 | Matrix Stiffness Normalization via Targeted Lysyl Oxidase Inhibition | LOX/LOXL1-4 | 0.709 | $0.73 | sda-2026-04-01-gap-v |
| #209 | Membrane Cholesterol Gradient Modulators | ABCA1/LDLR/SREBF2 | 0.708 | $0.73 | SDA-2026-04-01-gap-l |
| #210 | Orexin-Microglia Modulation Therapy | HCRTR2 | 0.707 | $0.74 | sda-2026-04-01-gap-v |
| #211 | Creatine Kinase System Capacity as Neural Energy Reserve Biomarker | CKB | 0.707 | $0.70 | SDA-2026-04-04-gap-d |
| #212 | TET2-Mediated Demethylation Rejuvenation Therapy | TET2 | 0.706 | $0.73 | sda-2026-04-01-gap-v |
| #213 | Lysosomal Enzyme Trafficking Correction | IGF2R | 0.706 | $0.73 | sda-2026-04-01-gap-0 |
| #214 | Endothelial Glycocalyx Regeneration via Syndecan-1 Upregulation | SDC1 | 0.705 | $0.73 | sda-2026-04-01-gap-v |
| #215 | Test: TREM2 enhances amyloid clearance | - | 0.705 | $0.70 | - |
| #216 | Ferroptosis Inhibition for α-Synuclein Neuroprotection | GPX4 | 0.705 | $0.73 | SDA-2026-04-03-gap-a |
| #217 | Microglial Efferocytosis Enhancement via GPR32 Superagonists | CMKLR1 | 0.704 | $0.73 | sda-2026-04-01-gap-0 |
| #218 | Multiplexed Base Editing for Simultaneous Neuroprotective Gene Activation | SOD1, TARDBP, BDNF, GDNF, IGF-1 | 0.704 | $0.74 | SDA-2026-04-03-gap-c |
| #219 | Purinergic P2Y12 Inverse Agonist Therapy | P2RY12 | 0.703 | $0.73 | sda-2026-04-01-gap-v |
| #220 | Microglial Exosome-Mediated Tau Propagation | MAPT | 0.702 | $0.67 | SDA-2026-04-03-26abc |
| #221 | Mitochondrial-Nuclear Epigenetic Cross-Talk Restoration | SIRT3 | 0.701 | $0.73 | SDA-2026-04-04-gap-e |
| #222 | DAMP-Scavenging Microglial Reset | HMGB1, S100 proteins | 0.701 | $0.73 | SDA-2026-04-04-gap-n |
| #223 | Microglial Purinergic Reprogramming | P2RY12 | 0.701 | $0.73 | sda-2026-04-01-gap-0 |
| #224 | Transglutaminase-2 Cross-Linking Inhibition Strategy | TGM2 | 0.701 | $0.73 | sda-2026-04-01-gap-9 |
| #225 | Targeted Butyrate Supplementation for Microglial Phenotype Modulation | GPR109A | 0.700 | $0.73 | SDA-2026-04-01-gap-2 |
| #226 | TREM2 haploinsufficiency dysregulates microglial synaptic surveillance, switching from protective 'disease-associated microglia' to neurotoxic 'inflammasome-active' states | TREM2, TYROBP (DAP12), APOE | 0.700 | $0.70 | SDA-2026-04-02-gap-s |
| #227 | AAV-Mediated APOE2/APOE3 Gene Delivery to Convert APOE Genotype | APOE | 0.700 | $0.70 | SDA-2026-04-02-gap-a |
| #228 | Mechanosensitive Ion Channel Reprogramming | PIEZO1 and KCNK2 | 0.700 | $0.72 | sda-2026-04-01-gap-0 |
| #229 | TREM2-Mediated Selective Aggregate Clearance Pathway | TREM2 | 0.699 | $0.73 | sda-2026-04-01-gap-9 |
| #230 | Granzyme B Inhibition with Serpina3n to Preserve Axonal Integrity Against Cytotoxic Attack | GZMB | 0.698 | $0.73 | SDA-2026-04-15-gap-d |
| #231 | H5: C9orf72 DPR Dipeptides Corrupt G3BP1 Condensate Properties | C9orf72, G3BP1 | 0.698 | $0.70 | SDA-2026-04-06-gap-p |
| #232 | TFEB-Independent Autophagy Bypass | ULK1 | 0.697 | $0.65 | SDA-2026-04-03-gap-d |
| #233 | Lysosomal Calcium Channel Modulation Therapy | MCOLN1 | 0.697 | $0.73 | sda-2026-04-01-gap-0 |
| #234 | Perforant Path Presynaptic Terminal Protection Strategy | PPARGC1A | 0.696 | $0.72 | sda-2026-04-01-gap-0 |
| #235 | Dual-Circuit Tau Vulnerability Cascade with Glial-Mediated Amplification | MAPT | 0.696 | $0.73 | SDA-2026-04-03-26abc |
| #236 | Axonal RNA Transport Reconstitution | HNRNPA2B1 | 0.695 | $0.73 | sda-2026-04-01-gap-v |
| #237 | Mitochondrial Transfer Pathway Enhancement | MIRO1 | 0.695 | $0.73 | sda-2026-04-01-gap-0 |
| #238 | Temporal Microglial State Switching | Optogenetic constructs, ion channels | 0.695 | $0.73 | SDA-2026-04-04-gap-n |
| #239 | Complement C1q Mimetic Decoy Therapy | C1QA | 0.695 | $0.72 | sda-2026-04-01-gap-v |
| #240 | Astrocytic Lipoxin A4 Pathway Restoration via ALOX15 Gene Therapy | ALOX15 | 0.695 | $0.72 | sda-2026-04-01-gap-0 |
| #241 | Palmitoylation-Targeted BACE1 Trafficking Disruptors | BACE1 | 0.693 | $0.73 | SDA-2026-04-01-gap-l |
| #242 | Astrocytic Connexin-43 Upregulation Enhances Neuroprotective Mitochondrial Donation | GJA1 | 0.692 | $0.72 | sda-2026-04-01-gap-2 |
| #243 | Ocular Immune Privilege Extension | FOXP3/TGFB1 | 0.692 | $0.72 | sda-2026-04-01-gap-0 |
| #244 | Sphingomyelin Synthase Activators for Raft Remodeling | SGMS1/SGMS2 | 0.692 | $0.72 | SDA-2026-04-01-gap-l |
| #245 | TREM2-Mediated Microglial Dysfunction Disrupts Oligodendrocyte Tau Clearance Networks | TREM2 | 0.691 | $0.74 | SDA-2026-04-03-26abc |
| #246 | TREM2-Dependent Microglial Surveillance Controls AQP4-Mediated Tau Clearance Through Astrocytic Endfoot Maintenance | TREM2 | 0.691 | $0.74 | SDA-2026-04-03-26abc |
| #247 | cGAS-STING Senescence Circuit Disruption | CGAS, STING1 | 0.691 | $0.72 | SDA-2026-04-03-gap-a |
| #248 | Extracellular Matrix Stiffness Modulation | PIEZO1 | 0.691 | $0.72 | sda-2026-04-01-gap-0 |
| #249 | Epigenetic Memory Reprogramming via CRISPRa-Mediated Chromatin Remodeling | SIRT1, FOXO3, NRF2, TFAM | 0.690 | $0.72 | SDA-2026-04-03-gap-c |
| #250 | TREM2 Agonism to Rescue APOE4-Induced Microglial Dysfunction | TREM2 | 0.690 | $0.69 | SDA-2026-04-02-gap-a |
| #251 | TREM2-Dependent Microglial State Transition as Therapeutic Window in Alzheimer's Disease | TREM2, SYK signaling pathway | 0.690 | $0.69 | SDA-2026-04-02-gap-2 |
| #252 | Loss of AQP4 Polarization Impairs Glymphatic Perivascular Influx, Causing Metabolite Accumulation | AQP4 | 0.690 | $0.69 | SDA-2026-04-07-gap-p |
| #253 | Astrocyte Reactivity Heterogeneity with APOE4-Dependent Vulnerability | APOE | 0.690 | $0.69 | SDA-2026-04-02-gap-s |
| #254 | Rab27A/B-mediated exosomal tau secretion from microglia drives frontal cortex propagation at Braak III-VI | RAB27A | 0.690 | $0.69 | SDA-2026-04-07-gap-d |
| #255 | Ganglioside Rebalancing Therapy | ST3GAL2/ST8SIA1 | 0.690 | $0.72 | SDA-2026-04-01-gap-l |
| #256 | Endothelial NRF2 Activation as a Master Switch for Post-CA BBB Protection | NRF2 (NFE2L2) in brain microvascular endothelial cells | 0.689 | $0.81 | SDA-2026-04-16-gap-p |
| #257 | Reelin-Mediated Cytoskeletal Stabilization Protocol | RELN | 0.689 | $0.72 | sda-2026-04-01-gap-0 |
| #258 | Cross-Seeding Prevention Strategy | TARDBP | 0.689 | $0.72 | sda-2026-04-01-gap-v |
| #259 | Hypocretin-Neurogenesis Coupling Therapy | HCRT | 0.688 | $0.72 | sda-2026-04-01-gap-v |
| #260 | Lysosomal Positioning Dynamics Modulation | LAMP1 | 0.686 | $0.72 | sda-2026-04-01-gap-0 |
| #261 | Wnt/β-catenin Pathway Restoration | CTNNB1 | 0.686 | $0.72 | SDA-2026-04-16-gap-b |
| #262 | CX43 hemichannel engineering enables size-selective mitochondrial transfer | GJA1 | 0.686 | $0.72 | sda-2026-04-01-gap-v |
| #263 | TREM2 Conformational Stabilizers for Synaptic Discrimination | TREM2 | 0.685 | $0.72 | sda-2026-04-01-gap-v |
| #264 | GLUT1-Mediated Glucose Flux Coefficient as Neuroprotection Indicator | SLC2A1 | 0.685 | $0.69 | SDA-2026-04-04-gap-d |
| #265 | Pericyte Contractility Reset via Selective PDGFR-β Agonism | PDGFRB | 0.684 | $0.72 | sda-2026-04-01-gap-v |
| #266 | Astrocyte-Selective APOE4 Silencing via Lipid Nanoparticles | APOE4 | 0.682 | $0.70 | SDA-2026-04-03-gap-d |
| #267 | Context-Dependent CRISPR Activation in Specific Neuronal Subtypes | Cell-type-specific essential genes | 0.682 | $0.71 | SDA-2026-04-03-gap-c |
| #268 | Flotillin-1 Stabilization Compounds | FLOT1 | 0.681 | $0.71 | SDA-2026-04-01-gap-l |
| #269 | CRISPR-Mediated Mitochondrial Genome Editing for Complex I Dysfunction | MT-ND1, MT-ND4, MT-ND6 | 0.681 | $0.72 | SDA-2026-04-03-gap-c |
| #270 | R-Loop Resolution Enhancement Therapy | SETX | 0.680 | $0.71 | sda-2026-04-01-gap-v |
| #271 | Chaperone-Mediated APOE4 Refolding Enhancement | HSPA1A, HSP90AA1, DNAJB1, FKBP5 | 0.680 | $0.70 | sda-2026-04-01-gap-0 |
| #272 | Osmotic Gradient Restoration via Selective AQP1 Enhancement in Choroid Plexus | AQP1 | 0.680 | $0.71 | sda-2026-04-01-gap-v |
| #273 | Pharmacological EZH2 Inhibition Resets Polycomb-Mediated Repression of Synaptic Transmission Genes in 3xTg-AD Neurons | EZH2/H3K27me3 | 0.680 | $0.68 | SDA-2026-04-04-gap-2 |
| #274 | LRP1-Mediated Transcytosis for CNS Antibody Delivery | LRP1 (LRP1 gene); clathrin-mediated endocytosis pathway | 0.680 | $0.68 | SDA-2026-04-02-gap-b |
| #275 | Synaptic Phosphatidylserine Masking via Annexin A1 Mimetics | ANXA1 | 0.680 | $0.71 | sda-2026-04-01-gap-v |
| #276 | TFEB-mediated transcriptional upregulation of lysosomal genes as a therapeutic strategy for AD | TFEB (TFEC) | 0.680 | $0.68 | SDA-2026-04-04-gap-l |
| #277 | Complement C1QA Spatial Gradient in Cortical Layers | C1QA | 0.678 | $0.70 | analysis-SEAAD-20260 |
| #278 | Dynamic Lactate-Pyruvate Ratio as Therapeutic Stratification Biomarker | SLC16A1 | 0.677 | $0.67 | SDA-2026-04-04-gap-d |
| #279 | Cell-Type Specific TFEB Modulation | TFEB | 0.677 | $0.70 | SDA-2026-04-03-gap-d |
| #280 | Astrocyte-Mediated Microglial Memory Erasure | GFAP, S100B | 0.677 | $0.71 | SDA-2026-04-04-gap-n |
| #281 | Selective Tau Kinase Inhibition in Vulnerable Neuronal Subtypes | MAPT | 0.676 | $0.71 | SDA-2026-04-03-gap-s |
| #282 | Microglial TREM2-Mediated Tau Phagocytosis Impairment | MAPT | 0.676 | $0.72 | SDA-2026-04-03-26abc |
| #283 | White Matter Oligodendrocyte Protection via CXCL10 Inhibition | CXCL10 | 0.675 | $0.70 | SDA-2026-04-03-gap-a |
| #284 | Excitatory Neuron Vulnerability via SLC17A7 Downregulation | SLC17A7 | 0.675 | $0.70 | analysis-SEAAD-20260 |
| #285 | RAB27A-dependent extracellular vesicle engineering for mitochondrial cargo delivery | RAB27A | 0.674 | $0.71 | sda-2026-04-01-gap-v |
| #286 | Metabolic Reprogramming via Microglial Glycolysis Inhibition | HK2 | 0.672 | $0.71 | sda-2026-04-01-gap-v |
| #287 | Astrocytic-Mediated Tau Clearance Dysfunction via TREM2 Signaling | TREM2 | 0.672 | $0.72 | SDA-2026-04-03-26abc |
| #288 | FOXO3-Longevity Pathway Epigenetic Reprogramming | FOXO3 | 0.672 | $0.71 | sda-2026-04-01-gap-v |
| #289 | Partial Neuronal Reprogramming via Modified Yamanaka Cocktail | OCT4 | 0.672 | $0.70 | SDA-2026-04-04-gap-e |
| #290 | Age-Dependent Complement C4b Upregulation Drives Synaptic Vulnerability in Hippocampal CA1 Neurons | C4B | 0.671 | $0.70 | SDA-2026-04-03-gap-a |
| #291 | TREM2 R47H variant synergizes with APOE4 to collapse microglial lipid clearance capacity, causing extracellular lipid accumulation that feeds back to astrocyte lipid droplet formation | TREM2, APOE | 0.670 | $0.67 | SDA-2026-04-04-gap-a |
| #292 | LPS-primed microglial trained immunity establishes persistent H3K4me3 landscapes at complement gene loci, driving hyperactive synaptic pruning in late-life neurodegeneration | NLRP3, H3K4me3 writers (MLL3/4, SETD1A), H3K27ac (EP300/CREBBP) | 0.670 | $0.67 | SDA-2026-04-02-gap-s |
| #293 | Restore AQP4 Perivascular Polarization by Stabilizing DAPC/SNTA1/DAG1 Anchoring Complex | AQP4, SNTA1, DAG1 | 0.670 | $0.67 | SDA-2026-04-07-gap-p |
| #294 | Enhancing Vagal Cholinergic Signaling to Restore Gut-Brain Anti-Inflammatory Communication | CHRNA7 | 0.669 | $0.70 | SDA-2026-04-01-gap-2 |
| #295 | Astrocyte MCT1/MCT4 Ratio Disruption with Metabolic Uncoupling | SLC16A1 | 0.668 | $0.70 | SDA-2026-04-03-gap-s |
| #296 | Heat Shock Protein 70 Disaggregase Amplification | HSPA1A | 0.668 | $0.70 | sda-2026-04-01-gap-0 |
| #297 | TREM2 Agonism Has Narrow Early-Window at DAM1→DAM2 Transition Checkpoint | TREM2, SYK signaling axis | 0.668 | $0.67 | SDA-2026-04-06-gap-d |
| #298 | Aquaporin-4 Polarization Enhancement via TREK-1 Channel Modulation | KCNK2 | 0.668 | $0.70 | sda-2026-04-01-gap-v |
| #299 | Mitochondrial-Lysosomal Contact Site Engineering | RAB7A | 0.668 | $0.70 | sda-2026-04-01-gap-0 |
| #300 | SIRT6-NAD+ Axis Enhancement Therapy | SIRT6 | 0.667 | $0.70 | sda-2026-04-01-gap-v |
| #301 | White Matter Vulnerability Prevention via Oligodendrocyte Protection | CXCL10 | 0.667 | $0.70 | SDA-2026-04-03-gap-a |
| #302 | Lipid Droplet Dynamics as Phenotype Switches | DGAT1 and SOAT1 | 0.666 | $0.70 | sda-2026-04-01-gap-0 |
| #303 | Glymphatic-Cholinergic Tau Clearance Cascade | MAPT | 0.666 | $0.70 | SDA-2026-04-03-26abc |
| #304 | GAP43-mediated tunneling nanotube stabilization enhances neuroprotective mitochondrial transfer | GAP43 | 0.666 | $0.70 | sda-2026-04-01-gap-v |
| #305 | EV-Mediated Epigenetic Reprogramming | EVs/miRNAs | 0.665 | $0.70 | sda-2026-04-12-ev-ad |
| #306 | Oligodendrocyte DNA Repair Enhancement Therapy | PARP1 and XRCC1 | 0.665 | $0.70 | SDA-2026-04-03-gap-s |
| #307 | Complement C1q Subtype Switching | C1QA | 0.665 | $0.70 | sda-2026-04-01-gap-0 |
| #308 | Gut Barrier Permeability-α-Synuclein Axis Modulation | CLDN1, OCLN, ZO1, MLCK | 0.663 | $0.69 | SDA-2026-04-01-gap-2 |
| #309 | Sphingolipid Metabolism Reprogramming | CERS2 | 0.663 | $0.70 | sda-2026-04-01-gap-0 |
| #310 | RNA Granule Nucleation Site Modulation | G3BP1 | 0.662 | $0.70 | sda-2026-04-01-gap-0 |
| #311 | Circadian-Metabolic Microglial Reprogramming | CLOCK, BMAL1, PER2 | 0.662 | $0.69 | SDA-2026-04-04-gap-n |
| #312 | Peripheral-Central Immune Decoupling Therapy | TREM2, complement cascade components | 0.662 | $0.69 | SDA-2026-04-04-gap-n |
| #313 | PARP1 Inhibition Blocks Poly(PR)-Triggered DNA Damage and Subsequent p53 Activation | PARP1 | 0.661 | $0.65 | SDA-2026-04-15-gap-p |
| #314 | EV-Mediated Epigenetic Reprogramming | EVs/miRNAs | 0.661 | $0.71 | sda-2026-04-12-ev-ad |
| #315 | Biorhythmic Interference via Controlled Sleep Oscillations | GABRA1 | 0.661 | $0.70 | sda-2026-04-01-gap-0 |
| #316 | BBB Integrity Loss Defines Absolute Therapeutic Window Closure | MMP-9, Claudin-5, PDGFRβ (pericyte coverage) | 0.660 | $0.66 | SDA-2026-04-06-gap-d |
| #317 | Vagal Afferent Microbial Signal Modulation | GLP1R, BDNF | 0.660 | $0.69 | SDA-2026-04-01-gap-2 |
| #318 | TREM2 Activation as an Amplification Node for R136S Protection | TREM2 | 0.657 | $0.65 | SDA-2026-04-13-gap-p |
| #319 | NLRP3 Inflammasome Blockade as Upstream Intervention to Prevent SASP Amplification | NLRP3 | 0.657 | $0.69 | SDA-2026-04-12-gap-d |
| #320 | Temporal TET2-Mediated Hydroxymethylation Cycling | TET2 | 0.657 | $0.70 | SDA-2026-04-04-gap-e |
| #321 | Liquid-Liquid Phase Separation Modifier Therapy | G3BP1 | 0.656 | $0.69 | sda-2026-04-01-gap-9 |
| #322 | Mitochondrial RNA Granule Rescue Pathway | SYNCRIP | 0.656 | $0.69 | sda-2026-04-01-gap-v |
| #323 | Time-Dependent BBB Repair Strategy | MULTIPLE | 0.656 | $0.70 | SDA-2026-04-16-gap-b |
| #324 | Optogenetic Microglial Deactivation via Engineered Inhibitory Opsins | CX3CR1 | 0.655 | $0.70 | sda-2026-04-01-gap-v |
| #325 | Test: TREM2 enhances amyloid clearance | - | 0.655 | $0.66 | - |
| #326 | Astrocyte-Microglia Communication Rebalancing via Cytokine Modulation | IL1A, TNF, C1Q | 0.655 | $0.69 | SDA-2026-04-03-gap-d |
| #327 | Arginine Methylation Enhancement Therapy | PRMT1 | 0.653 | $0.69 | sda-2026-04-01-gap-0 |
| #328 | KDM6A-Mediated H3K27me3 Rejuvenation | KDM6A | 0.653 | $0.69 | sda-2026-04-01-gap-v |
| #329 | Nucleolar Stress Response Normalization | NPM1 | 0.653 | $0.69 | sda-2026-04-01-gap-v |
| #330 | Locus Coeruleus-Hippocampal Circuit Protection | MAPT | 0.653 | $0.67 | SDA-2026-04-03-26abc |
| #331 | The Mitochondrial-Lysosomal Metabolic Coupling Dysfunction | TFEB | 0.652 | $0.69 | SDA-2026-04-02-gap-v |
| #332 | SUMO1-Mediated Synaptotagmin-1 SUMOylation at Lys124 Impairs Calcium Sensing and Links Synaptic Dysfunction to SASP-Complement Activation | SUMO1, SYT1, C1QA, C3 | 0.652 | $0.69 | SDA-2026-04-16-gap-d |
| #333 | Microbiota-Microglia Axis Modulation | Multiple | 0.651 | $0.68 | SDA-2026-04-04-gap-2 |
| #334 | Oligodendrocyte White Matter Vulnerability | MOG | 0.651 | $0.69 | SDA-2026-04-03-gap-a |
| #335 | Astrocyte APOE4-Specific Lipid Metabolism Correction | APOE | 0.651 | $0.69 | SDA-2026-04-03-gap-s |
| #336 | Prohibitin-2 Mitochondrial Cross-Seeding Hub Disruption | PHB2 | 0.650 | $0.69 | sda-2026-04-01-gap-9 |
| #337 | Mitochondrial Calcium Buffering Enhancement via MCU Modulation | MCU | 0.650 | $0.69 | sda-2026-04-01-gap-0 |
| #338 | Pharmacologically Boost AQP4X Readthrough to Restore Perivascular Clearance | AQP4, AQP4X | 0.650 | $0.65 | SDA-2026-04-07-gap-p |
| #339 | Galectin-3 deletion attenuates NLRP3 inflammasome activation downstream of lysosomal membrane permeabilization | LGALS3 | 0.650 | $0.65 | SDA-2026-04-04-gap-l |
| #340 | APOE-Mediated Synaptic Lipid Raft Stabilization | SPTLC1 | 0.649 | $0.68 | sda-2026-04-01-gap-a |
| #341 | Glycosaminoglycan Template Disruption Approach | HSPG2 | 0.649 | $0.68 | sda-2026-04-01-gap-9 |
| #342 | Glial Glycocalyx Remodeling Therapy | HSPG2 | 0.649 | $0.69 | sda-2026-04-01-gap-0 |
| #343 | TREM2-Mediated Oligodendrocyte-Microglia Metabolic Coupling in White Matter Neurodegeneration | TREM2 | 0.649 | $0.64 | SDA-2026-04-03-gap-a |
| #344 | Apoptosis-Senescence Decision Point Intervention | TP53,BAX,BAK1,CASP3 | 0.649 | $0.68 | SDA-2026-04-04-gap-s |
| #345 | APOE-TREM2 Ligand Availability Dysfunction in Neurodegeneration | APOE | 0.649 | $0.64 | SDA-2026-04-03-gap-a |
| #346 | TREM2-Mediated Mitochondrial Dysfunction in Neurodegeneration | TREM2 | 0.649 | $0.64 | SDA-2026-04-03-gap-a |
| #347 | CLU-APOE-TREM2 Tripartite Axis as a Coordinate Therapeutic Target | CLU-APOE-TREM2 axis (LXR/RXR pathway) | 0.648 | $0.64 | SDA-2026-04-14-gap-p |
| #348 | DNMT1-Targeting Antisense Oligonucleotide Reset | DNMT1 | 0.648 | $0.69 | sda-2026-04-01-gap-v |
| #349 | Mitochondrial SPM Synthesis Platform Engineering | ALOX5 | 0.647 | $0.69 | sda-2026-04-01-gap-0 |
| #350 | Epigenetic Reprogramming of Microglial Memory | DNMT3A, HDAC1/2 | 0.647 | $0.68 | SDA-2026-04-04-gap-2 |
| #351 | Grid Cell-Specific Metabolic Reprogramming via IDH2 Enhancement | IDH2 | 0.646 | $0.69 | sda-2026-04-01-gap-0 |
| #352 | NLRP3/Mitophagy Coupling Modulation | NLRP3 | 0.646 | $0.67 | SDA-2026-04-03-gap-i |
| #353 | Synthetic Biology Rewiring via Orthogonal Receptors | CNO | 0.645 | $0.69 | sda-2026-04-01-gap-0 |
| #354 | Miro1-Mediated Mitochondrial Trafficking Enhancement Therapy | RHOT1 | 0.645 | $0.68 | sda-2026-04-01-gap-2 |
| #355 | Ephrin-B2/EphB4 Axis Manipulation | EPHB4 | 0.645 | $0.68 | sda-2026-04-01-gap-0 |
| #356 | Oligodendrocyte Remyelination Enhancement | TREM2 | 0.644 | $0.67 | SDA-2026-04-03-gap-a |
| #357 | Dual Calpain/Cathepsin B Inhibition as Primary Neuroprotective Strategy | - | 0.644 | $0.63 | SDA-2026-04-15-gap-p |
| #358 | White Matter Immune Checkpoint Restoration | CXCL10 | 0.644 | $0.68 | SDA-2026-04-03-gap-a |
| #359 | HDAC6 Selective Inhibition to Restore Acetylation Balance and Microtubule Stability | HDAC6 | 0.643 | $0.63 | SDA-2026-04-13-gap-d |
| #360 | HDAC2 Phospho-Lock Window for Synaptic Gene Silencing | HDAC2 (phospho-S421) | 0.643 | $0.64 | SDA-2026-04-07-gap-d |
| #361 | Cell-Type Specific Metabolic Reprogramming | PPARA | 0.643 | $0.68 | SDA-2026-04-03-gap-s |
| #362 | TREM2-Driven Senescence Biomarker Index for Predicting Neurodegeneration Risk | TREM2 | 0.642 | $0.64 | SDA-2026-04-03-gap-a |
| #363 | Mitochondrial ATP/ADP Carrier Activity as Bioenergetic Recovery Metric | SLC25A4 | 0.642 | $0.67 | SDA-2026-04-04-gap-d |
| #364 | Targeting Bacterial Curli Fibrils to Prevent α-Synuclein Cross-Seeding | CSGA | 0.642 | $0.68 | SDA-2026-04-01-gap-2 |
| #365 | RNA-Binding Competition Therapy for TDP-43 Cross-Seeding | TARDBP | 0.642 | $0.68 | sda-2026-04-01-gap-9 |
| #366 | Glycine-Rich Domain Competitive Inhibition | TARDBP | 0.640 | $0.68 | sda-2026-04-01-gap-0 |
| #367 | CX3CR1 Promoter Methylation Disrupts Neuron-Microglia Cross-Talk | CX3CR1 | 0.640 | $0.64 | SDA-2026-04-07-gap-d |
| #368 | CDK5 Inhibition at Presynaptic Terminals Prevents Activity-Dependent Tau Release and Transsynaptic Propagation | CDK5 | 0.640 | $0.64 | SDA-2026-04-04-gap-2 |
| #369 | Autophagic Flux Enhancement Synergizes With Chaperones to Clear High-Molecular-Weight Tau Seeds | TFEB, LAMP2A, SQSTM1 | 0.640 | $0.64 | SDA-2026-04-06-gap-d |
| #370 | H7: mTOR Hyperactivity Blocks Autophagy, Permitting Tau Seeding | MTOR, ULK1, TFG | 0.640 | $0.64 | SDA-2026-04-02-gap-e |
| #371 | C1Q-Triggered NLRP3 Inflammasome Assembly in Plaque Macrophages | C1QA/C1QC | 0.640 | $0.64 | SDA-2026-04-07-gap-p |
| #372 | Heterogeneous astrocyte activation states differentially impact neuronal survival across AD progression | GFAP | 0.640 | $0.68 | SDA-2026-04-04-analy |
| #373 | Mitochondrial NAD+ Salvage Enhancement | STING1 | 0.639 | $0.67 | SDA-2026-04-03-gap-a |
| #374 | Acid-Degradable LNP-Mediated Prenatal CRISPR Intervention for Severe Neurodevelopmental Forms | SOD1, HTT, TARDBP | 0.638 | $0.67 | SDA-2026-04-03-gap-c |
| #375 | Selective Neuronal Vulnerability Network Targeting | Cell-type specific vulnerability markers | 0.638 | $0.67 | SDA-2026-04-03-gap-a |
| #376 | Stage-Selective TREM2 Agonism — Boosting DAM Phagocytosis in Early Amyloid Phase | TREM2 | 0.637 | $0.62 | SDA-2026-04-02-gap-0 |
| #377 | Test: TREM2 enhances amyloid clearance | - | 0.637 | $0.64 | - |
| #378 | Vascular mural cell degeneration precedes and exacerbates parenchymal pathology | PDGFRB | 0.637 | $0.66 | SDA-2026-04-04-analy |
| #379 | Astrocyte Metabolic Reprogramming via APOE4 Correction | APOE | 0.636 | $0.67 | SDA-2026-04-03-gap-s |
| #380 | TREM2-Dependent Microglial Phagocytosis Acts as a Strain Selection Filter | TREM2 | 0.636 | $0.62 | SDA-2026-04-15-gap-d |
| #381 | HSP90-Tau Disaggregation Complex Enhancement | HSP90AA1 | 0.634 | $0.68 | SDA-2026-04-04-gap-t |
| #382 | DLK MAPK Pathway Inhibition to Block Tau-Induced Neurotoxicity Without Directly Targeting Tau | MAP2K7/MAP3K12 | 0.634 | $0.67 | SDA-2026-04-15-gap-p |
| #383 | HSP70 Co-chaperone DNAJB6 Universal Cross-Seeding Inhibitor | DNAJB6 | 0.632 | $0.67 | sda-2026-04-01-gap-9 |
| #384 | Layer V excitatory neurons show selectively enhanced vulnerability through dysregulated calcium signaling | SLC17A7 | 0.632 | $0.65 | SDA-2026-04-04-analy |
| #385 | TREM2 R47H Variant Correction — AAV-Mediated Rescue of Common Risk Allele | TREM2 | 0.631 | $0.61 | SDA-2026-04-02-gap-0 |
| #386 | Gap Junction Hemichannel Modulation for Controlled Mitochondrial Exchange | PANX1 | 0.631 | $0.67 | sda-2026-04-01-gap-2 |
| #387 | CX3CR1 Agonism Enhances Microglial Phagocytosis of Extracellular Tau Seeds, Preventing Template-Dependent Misfolding | CX3CR1 | 0.630 | $0.63 | SDA-2026-04-04-gap-2 |
| #388 | Targeting Synaptic Vesicle Release Machinery to Block Tau Exocytosis | SNAP25 | 0.630 | $0.63 | SDA-2026-04-04-gap-t |
| #389 | Restoration of V-ATPase function reverses lysosomal acidification defect in AD neurons | ATP6V1A, ATP6V0C | 0.630 | $0.63 | SDA-2026-04-04-gap-l |
| #390 | Treat Glymphatic Failure by Coupling AQP4-Targeted Therapy to Sleep/Noradrenergic State | AQP4, ADRA2, LC | 0.630 | $0.63 | SDA-2026-04-07-gap-p |
| #391 | Selective Cholinergic Protection via APP Pathway Modulation | APP | 0.629 | $0.66 | SDA-2026-04-03-gap-a |
| #392 | APOE4-Driven Astrocyte Senescence as Primary Target | APOE,CDKN1A,BCL2L1 | 0.629 | $0.66 | SDA-2026-04-04-gap-s |
| #393 | Gut-Brain Axis M-Cell Modulation | GP2, SPIB | 0.629 | $0.66 | SDA-2026-04-04-gap-n |
| #394 | TREM2 Antagonism in Late-Stage Tauopathy — Reducing Neuroinflammatory Amplification | TREM2 | 0.628 | $0.61 | SDA-2026-04-02-gap-0 |
| #395 | Microglial TREM2 downregulation impairs damage-associated response in late-stage Alzheimer's disease | TREM2 | 0.628 | $0.67 | SDA-2026-04-04-analy |
| #396 | Quantum Coherence Disruption in Cellular Communication | TUBB3 | 0.627 | $0.69 | sda-2026-04-01-gap-0 |
| #397 | Synthetic Biology Approach: Designer Mitochondrial Export Systems | Synthetic fusion proteins | 0.627 | $0.67 | sda-2026-04-01-gap-2 |
| #398 | TREM2 Super-Agonist Induction of DAM Program | - | 0.627 | $0.63 | SDA-2026-04-16-gap-2 |
| #399 | Cardiovascular-Neuroinflammatory Dual Targeting | TNF/IL6 | 0.627 | $0.66 | SDA-2026-04-04-gap-2 |
| #400 | Default Mode Network Circuit Stabilization | VIP | 0.627 | $0.66 | SDA-2026-04-03-26abc |
| #401 | Microbial Metabolite-Mediated α-Synuclein Disaggregation | SNCA, HSPA1A, DNMT1 | 0.626 | $0.67 | SDA-2026-04-01-gap-2 |
| #402 | Peripheral-to-Central Inflammation Circuit Breaker | IL1B | 0.626 | $0.67 | SDA-2026-04-16-gap-b |
| #403 | Enteric Nervous System Prion-Like Propagation Blockade | TLR4, SNCA | 0.625 | $0.67 | SDA-2026-04-01-gap-2 |
| #404 | APOE4-Targeted Ultrasonic Lipidation Enhancement for Gamma Oscillation Restoration in Alzheimer's Disease | APOE/PVALB | 0.625 | $0.61 | - |
| #405 | PINK1/Parkin-Independent Mitophagy Bypass for Enhanced Donor Mitochondria | BNIP3/BNIP3L | 0.624 | $0.66 | sda-2026-04-01-gap-2 |
| #406 | Conditional CRISPR Kill Switches for Aberrant Protein Clearance | UBE3A, PARK2, PINK1 | 0.624 | $0.66 | SDA-2026-04-03-gap-c |
| #407 | Serine/Arginine-Rich Protein Kinase Modulation | SRPK1 | 0.624 | $0.67 | sda-2026-04-01-gap-0 |
| #408 | Microglial TREM2-Independent Pathway Activation | DAP12, SYK, PLCG2 | 0.623 | $0.66 | SDA-2026-04-03-gap-d |
| #409 | Myelin Sulfatide Restoration | GAL3ST1 | 0.623 | $0.66 | SDA-2026-04-03-gap-a |
| #410 | TFEB-PGC1α Mitochondrial-Lysosomal Decoupling | TFEB | 0.622 | $0.66 | SDA-2026-04-03-gap-a |
| #411 | Cholesterol-CRISPR Convergence Therapy for Neurodegeneration | HMGCR, LDLR, APOE regulatory regions | 0.622 | $0.65 | SDA-2026-04-03-gap-c |
| #412 | Pharmacological Enhancement of APOE4 Glycosylation | ST6GAL1, FUT8 | 0.622 | $0.66 | sda-2026-04-01-gap-0 |
| #413 | Dual-Phase Medium-Chain Triglyceride Intervention | HMGCS2/CPT1A | 0.622 | $0.61 | SDA-2026-04-04-gap-d |
| #414 | Microglial ACE Enhancement for Amyloid Clearance | ACE | 0.622 | $0.65 | SDA-2026-04-03-gap-a |
| #415 | Designer TRAK1-KIF5 fusion proteins accelerate therapeutic mitochondrial delivery | TRAK1_KIF5A | 0.621 | $0.66 | sda-2026-04-01-gap-v |
| #416 | J-protein co-chaperone repertoire enables selective recognition of pathogenic conformers | DNAJB6, DNAJB2, HSPA8, HSPA1A | 0.620 | $0.62 | SDA-2026-04-10-gap-d |
| #417 | Chaperone-Degradation Coupling Prevents Aggregate Persistence by Shunting Seeds to the Proteasome | STUB1 (CHIP), UPS pathway | 0.620 | $0.62 | SDA-2026-04-06-gap-d |
| #418 | Cross-Cell Type Synaptic Rescue via Tripartite Synapse Restoration | SYN1, SLC1A2, and CX3CR1 | 0.620 | $0.65 | SDA-2026-04-03-gap-s |
| #419 | TREM2 Agonism to Reprogram Infiltrated Monocytes Toward Neuroprotective Phenotype | TREM2 | 0.620 | $0.61 | SDA-2026-04-13-gap-d |
| #420 | BMP4 Pathway Inhibition for Oligodendrocyte Myelination Support | BMP4 and BMPR1A | 0.620 | $0.66 | SDA-2026-04-03-gap-s |
| #421 | Subtle NMDAR Inhibition Attenuates Excitotoxicity-Driven Tau Release from Hypersynchronized Circuits | GRIN2B | 0.620 | $0.62 | SDA-2026-04-04-gap-2 |
| #422 | Tau fibrils expose neuronal phosphatidylserine and heat-shock protein 70, driving microglial non-complement synaptic engulfment in primary tauopathies | Phosphatidylserine, TIMD4, HSPA1A/HSPA1B, SCARF1, LRP8 | 0.620 | $0.62 | SDA-2026-04-02-gap-s |
| #423 | Synaptic RNA Metabolism Dysregulation | TARDBP | 0.620 | $0.62 | SDA-2026-04-08-gap-p |
| #424 | Lysosomal pH Restoration Upstream of TFEB | ATP6V1A | 0.619 | $0.65 | SDA-2026-04-03-gap-d |
| #425 | Neuronal Integrated Stress Response Modulation | EIF2AK3 (PERK) and EIF2B complex | 0.618 | $0.65 | SDA-2026-04-03-gap-s |
| #426 | PDGF-BB/PDGFRβ/STAT3 Paracrine Signaling Axis Mediates Aβ-Induced SPP1 Upregulation | SPP1 | 0.618 | $0.62 | SDA-2026-04-06-gap-p |
| #427 | Low Complexity Domain Cross-Linking Inhibition | TGM2 | 0.617 | $0.66 | sda-2026-04-01-gap-0 |
| #428 | LRP1/NLRP3/IL-1β Cascade Links Aβ Endocytosis to Inflammasome Activation and SPP1 Induction | SPP1 | 0.617 | $0.62 | SDA-2026-04-06-gap-p |
| #429 | Perinatal Immune Challenge Prevention | Multiple | 0.616 | $0.65 | SDA-2026-04-04-gap-2 |
| #430 | NAMPT-Centered NAD+ Restoration to Reverse Basal Forebrain Cholinergic Neuron Metabolic Failure | NAMPT,SIRT1,PGC1A | 0.616 | $0.65 | SDA-2026-04-16-gap-p |
| #431 | Mitochondrial-Cytokine Axis Modulation | Mitochondrial respiratory complexes and inflammatory cytokine receptors | 0.616 | $0.65 | SDA-2026-04-03-gap-a |
| #432 | Spatially-Targeted Regional Vulnerability Prevention | Regional vulnerability genes | 0.616 | $0.65 | SDA-2026-04-03-gap-s |
| #433 | Dose-Response Framework: PINK1/Parkin Mitophagy as the Critical Mediator Linking HBOT Parameters to Tau Clearance | - | 0.614 | $0.60 | SDA-2026-04-16-gap-p |
| #434 | Blocking AGE-RAGE Signaling in Enteric Glia to Prevent Neuroinflammatory Cascade | AGER | 0.613 | $0.65 | SDA-2026-04-01-gap-2 |
| #435 | Restoring Neuroprotective Tryptophan Metabolism via Targeted Probiotic Engineering | TDC | 0.612 | $0.64 | SDA-2026-04-01-gap-2 |
| #436 | Optogenetic Control of Mitochondrial Transfer Networks | ChR2 | 0.612 | $0.65 | sda-2026-04-01-gap-2 |
| #437 | Complement-Mediated Synaptic Pruning Dysregulation | C1QA | 0.612 | $0.65 | SDA-2026-04-03-gap-a |
| #438 | Test: TREM2 enhances amyloid clearance | - | 0.612 | $0.61 | - |
| #439 | Synaptic Pruning Precision Therapy | C1QA, C3, CX3CR1, CX3CL1 | 0.612 | $0.65 | SDA-2026-04-04-gap-2 |
| #440 | CaMKII-Dependent Synaptic Circuit Amplification | CAMK2A | 0.611 | $0.65 | SDA-2026-04-03-26abc |
| #441 | HDAC3-Dependent A1 Astrocyte Commitment Window | HDAC3 | 0.611 | $0.61 | SDA-2026-04-07-gap-d |
| #442 | Epigenetic Memory Reprogramming for Alzheimer's Disease | BDNF, CREB1, synaptic plasticity genes | 0.611 | $0.64 | SDA-2026-04-03-gap-c |
| #443 | APOE4-Lipid Metabolism Correction | APOE | 0.610 | $0.64 | SDA-2026-04-04-gap-2 |
| #444 | H1: Senolytic Clearance of Senescent APOE4 Astrocytes | CDKN2A (p16Ink4a) | 0.610 | $0.61 | SDA-2026-04-06-gap-d |
| #445 | Blocking Tau Packaging into Small Extracellular Vesicles via ESCRT-III Pathway | PDGRIP1L (ALIX) | 0.610 | $0.61 | SDA-2026-04-04-gap-t |
| #446 | Tau Cross-Seeding and Interaction | MAPT | 0.610 | $0.61 | SDA-2026-04-08-gap-p |
| #447 | Astrocyte LRP1-mediated tau uptake and APOE4-dependent secretion creates regional susceptibility gradients | LRP1 | 0.610 | $0.61 | SDA-2026-04-07-gap-d |
| #448 | H2: Perforant Path Synapse Loss via Early Complement Cascade Activation | C1QA, C1QB, C3, ITGAM | 0.610 | $0.61 | SDA-2026-04-02-gap-e |
| #449 | APOE4 preferentially signals through LRP1 over LDLR, altering endosomal cholesterol trafficking and causing lysosomal cholesterol sequestration that drives lysosomal dysfunction and inflammation | LRP1, NPC1, CTSD | 0.610 | $0.61 | SDA-2026-04-04-gap-a |
| #450 | Ketone-Based Metabolic Switching to Restore PV Interneuron Function | SIRT3, PVALB | 0.609 | $0.60 | SDA-2026-04-16-gap-2 |
| #451 | Temporal TFEB Modulation Therapy | TFEB | 0.609 | $0.65 | SDA-2026-04-03-gap-d |
| #452 | The Glial Ketone Metabolic Shunt Hypothesis | HMGCS2 | 0.608 | $0.64 | SDA-2026-04-02-gap-v |
| #453 | P2RY12-mediated autophagy inhibition in cerebral VSMCs impairs CAA clearance | P2RY12 | 0.605 | $0.60 | SDA-2026-04-07-gap-p |
| #454 | Microbiome-Derived Tryptophan Metabolite Neuroprotection | AHR, IL10, TGFB1 | 0.605 | $0.65 | SDA-2026-04-01-gap-2 |
| #455 | TREM2-Microglial Clearance Enhancement as Common Mechanism for Injury Prevention | TREM2 | 0.604 | $0.59 | SDA-2026-04-14-gap-p |
| #456 | DAPK1 Inhibition as Dual-Mechanism Neuroprotection Against Tau-Induced Destabilization | DAPK1 | 0.604 | $0.63 | SDA-2026-04-15-gap-p |
| #457 | Selective TFEB Cofactor Enhancement | TFE3 | 0.602 | $0.64 | SDA-2026-04-03-gap-d |
| #458 | NRF2-Mediated Metabolic Reprogramming: HBOT as Direct NAMPT/SIRT1 Activator for Reverse Senescence | - | 0.602 | $0.60 | SDA-2026-04-16-gap-p |
| #459 | TREM2-Mediated Oligodendrocyte-Microglia Cross-talk in White Matter Neurodegeneration | TREM2 | 0.600 | $0.60 | SDA-2026-04-03-gap-a |
| #460 | APOE4 Induces Region-Specific Microglial Senescence Driving Frontal Cortex Neurodegeneration | APOE4 | 0.600 | $0.60 | SDA-2026-04-06-gap-p |
| #461 | TREM2-Dependent Senescent Microglia Disrupt Astrocyte Communication Networks | TREM2/TYROBP | 0.600 | $0.54 | SDA-2026-04-03-gap-a |
| #462 | TREM2-Mediated Astroglial Reactivity in Neurodegeneration | TREM2 | 0.600 | $0.60 | SDA-2026-04-03-gap-a |
| #463 | Oligodendrocyte-Targeted Myelin Sulfatide Restoration Therapy | CST, GAL3ST1 | 0.599 | $0.63 | SDA-2026-04-03-gap-d |
| #464 | Differential Interneuron Optogenetic Restoration Therapy | PVALB/SST | 0.599 | $0.63 | SDA-2026-04-03-26abc |
| #465 | OPC differentiation blockade contributes to white matter degeneration in early-stage AD | PDGFRA | 0.599 | $0.65 | SDA-2026-04-04-analy |
| #466 | Metabolic Reprogramming via Coordinated Multi-Gene CRISPR Circuits | PGC1A, SIRT1, FOXO3, mitochondrial biogenesis genes | 0.599 | $0.63 | SDA-2026-04-03-gap-c |
| #467 | Brain Insulin Resistance with Glucose Transporter Dysfunction | GLUT3/GLUT4 | 0.596 | $0.63 | SDA-2026-04-02-gap-v |
| #468 | Programmable Neuronal Circuit Repair via Epigenetic CRISPR | NURR1, PITX3, neuronal identity transcription factors | 0.596 | $0.63 | SDA-2026-04-03-gap-c |
| #469 | Multi-Modal CRISPR Platform for Simultaneous Editing and Monitoring | Disease-causing mutations with integrated reporters | 0.596 | $0.63 | SDA-2026-04-03-gap-c |
| #470 | Aβ-induced downregulation of circPDS5B derepresses TDP-43 mRNA translation in limbic neurons, causing proteostatic overload and aggregation specifically in AD | circPDS5B (hsa_circ_0083342) / TARDBP | 0.595 | $0.59 | SDA-2026-04-07-gap-p |
| #471 | Aβ42 oligomers drive TDP-43 phosphorylation at s409/410 through CDK5/p25 activation specifically in AD, generating a phospho-signature distinct from ALS/FTLD | CDK5R1 (p25 regulatory subunit) | 0.595 | $0.59 | SDA-2026-04-07-gap-p |
| #472 | Netrin-1 Gradient Restoration | NTN1 | 0.595 | $0.66 | sda-2026-04-01-gap-0 |
| #473 | TREM2-mediated microglial tau clearance enhancement | TREM2 | 0.594 | $0.84 | SDA-2026-04-04-gap-t |
| #474 | TREM2 Signaling Bifurcation with Independent TYROBP-Independent Homeostatic Maintenance | TREM2 | 0.591 | $0.60 | SDA-2026-04-14-gap-p |
| #475 | AP1S1-Mediated Vesicular Transport Restoration | AP1S1 | 0.588 | $0.62 | SDA-2026-04-03-gap-a |
| #476 | Cardiovascular-Neuroinflammation Crosstalk Interruption | IL1B, TNFA, NLRP3 | 0.587 | $0.62 | SDA-2026-04-04-gap-2 |
| #477 | Microglia-Derived Extracellular Vesicle Engineering for Targeted Mitochondrial Delivery | RAB27A/LAMP2B | 0.587 | $0.63 | sda-2026-04-01-gap-2 |
| #478 | TNFRSF25-Mediated Aging Exosome Pathway Inhibition | TNFRSF25 | 0.587 | $0.62 | SDA-2026-04-03-gap-a |
| #479 | Senescence-Tau Decoupling Therapy | CDKN2A | 0.585 | $0.62 | SDA-2026-04-03-gap-a |
| #480 | Mitochondrial-Lysosomal Coupling Enhancer | LAMTOR1 | 0.585 | $0.62 | SDA-2026-04-03-gap-d |
| #481 | Gut-Brain Axis Microbiome Modulation | GPR43, GPR109A | 0.585 | $0.62 | SDA-2026-04-04-gap-2 |
| #482 | P2RY12-driven autophagy impairment in cerebral VSMCs mediates BBB breakdown and neurovascular unit dysfunction | P2RY12 | 0.585 | $0.58 | SDA-2026-04-07-gap-p |
| #483 | APOE4 Creates Accelerated, Compressed Reversibility Window | APOE/TREM2 axis, APOE-TREM2 physical interaction | 0.584 | $0.58 | SDA-2026-04-06-gap-d |
| #484 | IGFBPL1-Mediated Homeostatic Restoration | IGFBPL1 | 0.584 | $0.62 | SDA-2026-04-04-gap-2 |
| #485 | FcRn Transport Bypass Strategy | LDLR | 0.583 | $0.62 | SDA-2026-04-12-gap-d |
| #486 | GPC4/HSPGs Collaborate with ApoE Isoforms to Dictate Tau Conformational Strain Uptake Efficiency | GPC4/APOE | 0.583 | $0.58 | SDA-2026-04-15-gap-d |
| #487 | Gamma Entrainment Synergy: HBOT-Enhanced Cerebral Perfusion Amplifies SST Interneuron-Targeted Neuromodulation | - | 0.583 | $0.57 | SDA-2026-04-16-gap-p |
| #488 | Pharmacological P2RY12 inhibition (ticagrelor/clopidogrel) as repurposing probe for neurovascular outcomes | P2RY12 | 0.583 | $0.58 | SDA-2026-04-07-gap-p |
| #489 | APOE4 drives astrocyte metabolic reprogramming toward glycolysis via PGC-1α suppression, reducing fatty acid oxidation and promoting lipogenesis that feeds pathological lipid droplet formation | PPARGC1A (PGC-1α), SIRT1, SREBF1 (SREBP1c) | 0.580 | $0.58 | SDA-2026-04-04-gap-a |
| #490 | APOE4 Structural Correction by Small Molecule Correctors | APOE4 | 0.580 | $0.58 | SDA-2026-04-02-gap-a |
| #491 | Neuroinflammation-Driven TDP-43 Mislocalization via Microglial APOE4 Signaling | NLRP3, LRP1, IL1B, TNF | 0.580 | $0.58 | SDA-2026-04-07-gap-p |
| #492 | Structure-interacting small molecules that stabilize the APOE4 molten globule domain (Domain III) can restore near-wildtype lipid-binding capacity, reducing lipid droplet pathology | APOE (protein structure stabilizer) | 0.580 | $0.58 | SDA-2026-04-04-gap-a |
| #493 | AQP4 Missorting in Reactive Astrocytes Drives Glymphatic Failure in Chronic Neurodegeneration | AQP4; STAT3; MMP9 | 0.580 | $0.58 | SDA-2026-04-07-gap-p |
| #494 | H5: Complement Dysregulation Drives Synapse Loss via Senescent APOE4 Astrocytes | C3; C3AR1; C5AR1 | 0.580 | $0.58 | SDA-2026-04-06-gap-d |
| #495 | TREM2 Promoter Silencing via DNA Hypermethylation | TREM2 | 0.580 | $0.58 | SDA-2026-04-07-gap-d |
| #496 | H7: Dual-Target Strategy (Senolytics + APOE4→3 Conversion) | APOE; CDKN2A | 0.580 | $0.58 | SDA-2026-04-06-gap-d |
| #497 | Oxygen Pressure-Dependent BDNF Cascade: DHHC2/PSD95 Stabilization for Synaptic Rescue | - | 0.580 | $0.57 | SDA-2026-04-16-gap-p |
| #498 | CHIP-mediated ubiquitination selectively targets oligomeric pathologic conformers for proteasomal degradation | STUB1 (CHIP), HSPA8, VCP, PSMD4 | 0.580 | $0.58 | SDA-2026-04-10-gap-d |
| #499 | Complement-Mediated Synaptic Protection | C1QA | 0.580 | $0.62 | SDA-2026-04-04-gap-2 |
| #500 | IGFBPL1-Mediated Microglial Reprogramming | IGFBPL1 | 0.579 | $0.62 | SDA-2026-04-04-gap-2 |
| #501 | Spatial Transcriptome-Guided Precision Cell Therapy | SOX10 and DLX1/2 | 0.578 | $0.62 | SDA-2026-04-03-gap-s |
| #502 | Dynamic Microglial Phenotype Switching Biomarker Panel for Neuroinflammatory Treatment Stratification | TREM2 | 0.577 | $0.58 | SDA-2026-04-16-gap-p |
| #503 | LRP1-Dependent Tau Uptake Disruption | LRP1 | 0.576 | $0.79 | SDA-2026-04-04-gap-t |
| #504 | Oligodendrocyte Progenitor Cell Metabolic Reprogramming | PDK1, PFKFB3, LDHA | 0.575 | $0.61 | SDA-2026-04-03-gap-d |
| #505 | TREM2-P2RY12 Balance Restoration Therapy | TREM2 | 0.571 | $0.61 | SDA-2026-04-04-gap-2 |
| #506 | VCP-Mediated Autophagy Enhancement | VCP | 0.571 | $0.76 | SDA-2026-04-04-gap-t |
| #507 | Blocking Exosomal Tau Uptake at Neuronal LRP1 Receptors Disrupts Interneuronal Propagation | LRP1 | 0.570 | $0.57 | SDA-2026-04-04-gap-2 |
| #508 | Blocking Astrocyte-Mediated Tau Re-Spreading via Cx43 Hemichannel Inhibition | GJA1 (Connexin-43) | 0.570 | $0.57 | SDA-2026-04-04-gap-t |
| #509 | LRP1-mediated synaptic uptake drives early entorhinal-hippocampal tau propagation (Braak I-II) | LRP1 | 0.570 | $0.57 | SDA-2026-04-07-gap-d |
| #510 | Hsp70-based therapy to prevent lysosomal membrane permeabilization and cathepsin release in AD | HSPA1A | 0.570 | $0.57 | SDA-2026-04-04-gap-l |
| #511 | Tau-Independent Microtubule Stabilization via MAP6 Enhancement | MAP6 | 0.567 | $0.73 | sda-2026-04-01-gap-0 |
| #512 | Synergistic enhancement of autophagy and lysosomal biogenesis by combined mTOR inhibition and TFEB activation | MTOR, TPCN2, TFEB | 0.565 | $0.57 | SDA-2026-04-04-gap-l |
| #513 | Temporal Gating of Microglial Responses | CLOCK, ARNTL | 0.565 | $0.63 | SDA-2026-04-04-gap-2 |
| #514 | Closed-loop transcranial focused ultrasound to restore hippocampal gamma oscillations via glymphatic-mediated amyloid clearance and secondary PV interneuron disinhibition in Alzheimer's disease | AQP4 | 0.564 | $0.56 | SDA-2026-04-03-26abc |
| #515 | Closed-loop transcranial focused ultrasound targeting entorhinal PV interneurons to restore AnkyrinG-dependent AIS integrity and hippocampal gamma synchrony in Alzheimer's disease | PVALB | 0.564 | $0.56 | SDA-2026-04-03-26abc |
| #516 | Closed-loop transcranial focused ultrasound to restore hippocampal gamma oscillations via indirect somatostatin interneuron disinhibition in Alzheimer's disease | SST | 0.564 | $0.56 | SDA-2026-04-03-26abc |
| #517 | Closed-loop tACS targeting EC-II somatostatin interneurons to restore dendritic integration and prevent tau-mediated HCN channel dysfunction in AD | SST | 0.564 | $0.56 | SDA-2026-04-03-26abc |
| #518 | Closed-loop transcranial focused ultrasound with real-time gamma feedback to restore PV interneuron function in Alzheimer's disease | PVALB | 0.564 | $0.56 | SDA-2026-04-03-26abc |
| #519 | Fractalkine Axis Amplification via CX3CR1 Positive Allosteric Modulators | CX3CR1 | 0.563 | $0.69 | sda-2026-04-01-gap-v |
| #520 | HCN1-Mediated Resonance Frequency Stabilization Therapy | HCN1 | 0.562 | $0.73 | sda-2026-04-01-gap-0 |
| #521 | H3: Reelin Signaling Deficiency Uncouples Layer II Neurons from Grid Cell Coupling | RELN, LRP8, GSK3B | 0.560 | $0.56 | SDA-2026-04-02-gap-e |
| #522 | TFEB Activation Clears Tau-Loaded Endolysosomal Compartments, Preventing Release for Transcellular Spreading | TFEB | 0.560 | $0.56 | SDA-2026-04-04-gap-2 |
| #523 | Multi-Chaperone System Co-Activation Prevents Saturation Through Complementary Substrate Recognition | DNAJB1, HSP90AA1/HSP90AB1, STIP1 (HOP) | 0.560 | $0.56 | SDA-2026-04-06-gap-d |
| #524 | Real-time closed-loop transcranial focused ultrasound targeting PVALB interneurons with continuous gamma oscillation feedback monitoring for precision neuromodulation in Alzheimer's disease | PVALB | 0.559 | $0.56 | SDA-2026-04-03-26abc |
| #525 | Extracellular Vesicle Biogenesis Modulation | CHMP4B | 0.558 | $0.68 | SDA-2026-04-04-gap-t |
| #526 | Circadian-Gated Maresin Biosynthesis Amplification | ALOX12 | 0.557 | $0.74 | sda-2026-04-01-gap-0 |
| #527 | Test: TREM2 enhances amyloid clearance | - | 0.555 | $0.55 | - |
| #528 | Optogenetic restoration of hippocampal gamma oscillations via channelrhodopsin-2 expression in PV interneurons for Alzheimer's disease treatment | PVALB | 0.555 | $0.00 | SDA-2026-04-03-26abc |
| #529 | Ketone-Primed Thalamocortical Enhancement of Glymphatic Tau Clearance | GRIN2B | 0.555 | $0.56 | SDA-2026-04-03-26abc |
| #530 | GluN2B-Mediated Microglial Activation and Tau Propagation | GRIN2B | 0.555 | $0.56 | SDA-2026-04-03-26abc |
| #531 | Inhibitory Neuron-Selective WNT Signaling Restoration | WNT3A, CTNNB1, TCF7L2 | 0.554 | $0.62 | SDA-2026-04-03-gap-d |
| #532 | Synaptic Vesicle Tau Capture Inhibition | SNAP25 | 0.554 | $0.69 | SDA-2026-04-04-gap-t |
| #533 | Profilin-1 Cytoskeletal Checkpoint Enhancement | PFN1 | 0.554 | $0.60 | SDA-2026-04-03-gap-a |
| #534 | Dual NF-κB/MMP Inhibition Strategy | NFKB1 | 0.554 | $0.57 | SDA-2026-04-16-gap-b |
| #535 | APOE4 Isoform Correction via Lipidation Enhancement as CTE Risk Mitigation | APOE | 0.552 | $0.54 | SDA-2026-04-14-gap-p |
| #536 | Closed-loop transcranial focused ultrasound to restore hippocampal gamma oscillations via astrocytic calcium signaling and potassium buffering in Alzheimer's disease | AQP4 | 0.551 | $0.00 | SDA-2026-04-03-26abc |
| #537 | Astrocytic SPP1 Modulation Through STAT3-Dependent Transcriptional Control | SPP1 | 0.551 | $0.55 | SDA-2026-04-15-gap-p |
| #538 | HSP90-Tau Disaggregation Complex Enhancement | HSP90AA1 | 0.551 | $0.80 | SDA-2026-04-04-gap-t |
| #539 | Disrupting Muscarinic M1/M3 Receptor-Mediated Tau Internalization and Synaptic Targeting | CHRM1 (M1R) | 0.550 | $0.55 | SDA-2026-04-04-gap-t |
| #540 | Oligodendrocyte DNA Repair Enhancement | PARP1 | 0.550 | $0.59 | SDA-2026-04-03-gap-s |
| #541 | Digital Twin-Guided Metabolic Reprogramming | PPARGC1A/PRKAA1 | 0.550 | $0.70 | sda-2026-04-01-gap-0 |
| #542 | YWHAG-Mediated TFEB Subcellular Targeting | YWHAG | 0.549 | $0.62 | SDA-2026-04-03-gap-d |
| #543 | Perinatal Hypoxia-Primed Microglia Targeting | HIF1A, NFKB1 | 0.548 | $0.59 | SDA-2026-04-04-gap-2 |
| #544 | Synaptic Vesicle Tau Capture Inhibition | SNAP25 | 0.547 | $0.59 | SDA-2026-04-04-gap-t |
| #545 | Sensory-Motor Circuit Cross-Modal Compensation | CHAT | 0.546 | $0.59 | SDA-2026-04-03-26abc |
| #546 | CD300f Immune Checkpoint Activation | CD300F | 0.545 | $0.61 | SDA-2026-04-03-gap-a |
| #547 | Trans-Synaptic Adhesion Molecule Modulation | NLGN1 | 0.544 | $0.63 | SDA-2026-04-04-gap-t |
| #548 | Temporal Decoupling via Circadian Clock Reset | CLOCK | 0.543 | $0.77 | sda-2026-04-01-gap-0 |
| #549 | TREM2-GluN2B Circuit: Microglial Control of Thalamocortical Oscillations and Glymphatic Tau Clearance | TREM2 | 0.543 | $0.00 | SDA-2026-04-03-26abc |
| #550 | Real-time closed-loop transcranial focused ultrasound targeting PV interneurons with API-integrated biomarker validation in Alzheimer's disease | PVALB | 0.542 | $0.00 | SDA-2026-04-03-26abc |
| #551 | H5: Olfactory System as a Toxicant Funnel into Layer II | NLRP3, CX3CR1, TLR4 | 0.540 | $0.54 | SDA-2026-04-02-gap-e |
| #552 | P2Y6R activation by UDP from damaged neurons drives microglial phagocytosis and exosomal re-secretion in mid-to-late disease | P2RY6 | 0.540 | $0.54 | SDA-2026-04-07-gap-d |
| #553 | Synaptic Vulnerability Window Temporal Targeting: Transient SPP1 Blockade | SPP1 | 0.540 | $0.54 | SDA-2026-04-07-gap-p |
| #554 | H6: Epigenetic Reset via APOE4→APOE3 Conversion Reverses Senescence | APOE; HDAC1; EZH2 | 0.540 | $0.54 | SDA-2026-04-06-gap-d |
| #555 | Lysosomal Membrane Repair Enhancement | CHMP2B | 0.538 | $0.72 | sda-2026-04-01-gap-0 |
| #556 | ABCA7-TREM2 Co-Targeting for Microglial Lipid Handling | ABCA7 + TREM2 (combinatorial) | 0.538 | $0.54 | SDA-2026-04-14-gap-p |
| #557 | Glymphatic System-Enhanced Antibody Clearance Reversal | AQP4 | 0.537 | $0.71 | sda-2026-04-01-gap-0 |
| #558 | Test: TREM2 enhances amyloid clearance | - | 0.537 | $0.54 | - |
| #559 | Gamma-Entrained PV Interneuron Networks Enable Precision p-tau217-Guided lncRNA Exosome Therapy in AD | PVALB, CREB1, lncRNA-0021/lncRNA-9969 | 0.536 | $0.54 | SDA-2026-04-16-gap-p |
| #560 | Cerebrospinal Fluid p-tau217-Guided Astrocyte-Derived Extracellular Vesicle Delivery of lncRNA-0021 in Early-Stage AD | CSF p-tau217 (biomarker), lncRNA-0021, astrocyte-derived extracellular vesicles | 0.536 | $0.54 | SDA-2026-04-16-gap-p |
| #561 | CD36 Acts as Primary Aβ Oligomer Sensor on Perivascular Macrophages, Triggering NF-κB-Dependent SPP1 Transcription | SPP1 | 0.535 | $0.74 | SDA-2026-04-06-gap-p |
| #562 | NFκB/C1Q SASP Modulation for Synaptic Protection | - | 0.534 | $0.53 | SDA-2026-04-16-gap-p |
| #563 | TREM2-Mediated Microglial Checkpoint Therapy | TREM2 | 0.534 | $0.58 | SDA-2026-04-03-gap-s |
| #564 | Blood-Brain Barrier SPM Shuttle System | TFRC | 0.533 | $0.76 | sda-2026-04-01-gap-0 |
| #565 | Cryptic Exon Silencing Restoration | TARDBP | 0.531 | $0.73 | sda-2026-04-01-gap-v |
| #566 | Modulating Tunneling Nanotube (TNT) Formation via M-Sec/Noradrenaline Signaling | TNFRSF12A (M-Sec) | 0.530 | $0.53 | SDA-2026-04-04-gap-t |
| #567 | NLRP3 Inflammasome Chromatin Priming Through H3K27ac Accumulation | NLRP3 | 0.530 | $0.53 | SDA-2026-04-07-gap-d |
| #568 | Therapeutic Repurposing: C1-INH as Plaque-Stabilizing Agent | C1R/C1S | 0.530 | $0.53 | SDA-2026-04-07-gap-p |
| #569 | C1Q-Angiogenic Axis Promoting Plaque Neovascularization | C1QA/C1QC | 0.530 | $0.53 | SDA-2026-04-07-gap-p |
| #570 | Astrocytic Lactate Shuttle Enhancement for Grid Cell Bioenergetics | SLC16A2 | 0.529 | $0.69 | sda-2026-04-01-gap-0 |
| #571 | DNMT1 Compensation Window During Synaptic Resilience Phase | DNMT1 | 0.528 | $0.53 | SDA-2026-04-07-gap-d |
| #572 | TREM2-Dependent Microglial Control of Thalamocortical-Glymphatic Tau Clearance | TREM2 | 0.524 | $0.00 | SDA-2026-04-03-26abc |
| #573 | TREM2 Agonism to Redirect Microglia from Synaptic Pruning to OPTN-Deficient Neuron Protection | TREM2 | 0.521 | $0.51 | SDA-2026-04-14-gap-p |
| #574 | Restoring AQP4 Astrocyte Polarization Enhances Glymphatic Tau Clearance and Limits Template-Dependent Spreading | AQP4 | 0.520 | $0.52 | SDA-2026-04-04-gap-2 |
| #575 | M-Sec/TNTA2-mediated tunneling nanotube formation drives glia-neuron tau propagation in mid-stages | TNFAIP2 | 0.520 | $0.52 | SDA-2026-04-07-gap-d |
| #576 | Therapeutic Window Exists Through Activity-Dependent Regulation of Synaptic Vesicle Priming | VAMP2, VAMP3, Complexin-1/2, Munc13-1 | 0.520 | $0.52 | SDA-2026-04-06-gap-d |
| #577 | Lipid Nanoparticle Encapsulation of IGFBPL1-mRNA | IGFBPL1 | 0.520 | $0.52 | SDA-2026-04-06-gap-d |
| #578 | Epigenetic Dysregulation of APOE Microglial Expression | APOE | 0.520 | $0.52 | SDA-2026-04-07-gap-d |
| #579 | Piezoelectric Nanochannel BBB Disruption | CLDN5, OCLN | 0.519 | $0.70 | sda-2026-04-01-gap-0 |
| #580 | Downstream Pathway Selective Modulation: ITGAX (αXβ2) Integrin Blockade | ITGAX (CD11c) | 0.519 | $0.52 | SDA-2026-04-07-gap-p |
| #581 | Stage-Dependent Biphasic SPP1 Targeting: Early Enhancement Followed by Late Inhibition | SPP1 | 0.518 | $0.52 | SDA-2026-04-07-gap-p |
| #582 | Hippocampus ages transcriptionally faster than cerebellum, defining a regional vulnerability axis conserved across species | CLU | 0.516 | $0.50 | aging-mouse-brain-20 |
| #583 | Vocal Cord Neuroplasticity Stimulation | CHR2/BDNF | 0.515 | $0.67 | sda-2026-04-01-gap-0 |
| #584 | GAS6/TAM Axis Activation Stabilizes Blood-Brain Barrier to Reduce Neuroinflammatory Cell Infiltration in Alzheimer's Disease | GAS6/TAM receptor complex | 0.513 | $0.51 | SDA-2026-04-14-gap-p |
| #585 | Test: TREM2 enhances amyloid clearance | - | 0.512 | $0.51 | - |
| #586 | Soluble GAG-Mimetic Peptides Compete with HSPG for Tau Seed Binding and Prevent Cellular Uptake | GPC1 | 0.510 | $0.51 | SDA-2026-04-04-gap-2 |
| #587 | Trans-Synaptic Adhesion Molecule Modulation | NLGN1 | 0.503 | $0.55 | SDA-2026-04-04-gap-t |
| #588 | NETosis Amplification by C1Q in Plaque Neutrophils | C1QA/C1QC | 0.500 | $0.50 | SDA-2026-04-07-gap-p |
| #589 | Autophagy-Lysosomal Flux Impairment Preventing Pathological TDP-43 Clearance | TFEB, LAMP1, LAMP2, GABARAPL1, CTSD | 0.500 | $0.50 | SDA-2026-04-07-gap-p |
| #590 | APOE4 astrocytes fail to supply sufficient cholesterol to parvalbumin interneurons, causing presynaptic GABA release deficits, disinhibition, and network hyperexcitability characteristic of AD | LDLR, LRP8 (ApoER2), APOE | 0.500 | $0.50 | SDA-2026-04-04-gap-a |
| #591 | TREM2-Mediated Microglial Dysfunction Drives Tau-Induced Blood-Brain Barrier Breakdown | TREM2 | 0.499 | $0.00 | SDA-2026-04-03-26abc |
| #592 | TREM2 on Perivascular Macrophages Senses Aβ and Drives SPP1 Upregulation Through CSF1R-Mediated Survival and Metabolic Signaling | SPP1 | 0.496 | $0.50 | SDA-2026-04-06-gap-p |
| #593 | TREM2-Mediated Microglial Metabolic Reprogramming Accelerates Tau Pathological Spread | TREM2 | 0.494 | $0.00 | SDA-2026-04-03-26abc |
| #594 | YAP/TAZ Mechanosensing Cooperates with NF-κB to Amplify SPP1 Transcription in Perivascular Fibroblasts | SPP1 | 0.492 | $0.70 | SDA-2026-04-06-gap-p |
| #595 | GluN2B-Regulated Microglial Phagocytosis of Tau Aggregates via CX3CR1 Signaling | GRIN2B | 0.491 | $0.00 | SDA-2026-04-03-26abc |
| #596 | Targeting AQP4 Sumoylation to Enhance Glymphatic Clearance as Therapeutic Strategy in Alzheimer's Disease | AQP4; SENP1; SENP2; UBC9 | 0.490 | $0.49 | SDA-2026-04-07-gap-p |
| #597 | Isoform-Selective Hsp70 Targeting Overcomes Stoichiometric Imbalance in Advanced Pathology | HSPA1A, DNAJB6, DNAJB8 | 0.490 | $0.70 | SDA-2026-04-06-gap-d |
| #598 | C1q-Mediated Delivery of miR-33 Antisense Oligonucleotides for Enhanced APOE4 Lipidation | miR-33a/miR-33b | 0.489 | $0.49 | SDA-2026-04-16-gap-d |
| #599 | SREBP-2 Direct Inhibition Hyper-Lipidation Strategy | SREBF2/ABCA1 | 0.489 | $0.49 | SDA-2026-04-16-gap-d |
| #600 | APOE4 Structural Remodeling via HSP70 Chaperone Enhancement Strategy | HSP70/APOE4 | 0.486 | $0.00 | SDA-2026-04-16-gap-d |
| #601 | GluN2B-Mediated Perivascular Pericyte Control of Glymphatic Tau Clearance | GRIN2B | 0.485 | $0.00 | SDA-2026-04-03-26abc |
| #602 | HDAC6 Inhibition for Dual Restoration of Microtubule Stability and Autophagic Tau Clearance | HDAC6 | 0.484 | $0.53 | SDA-2026-04-13-gap-d |
| #603 | Mitochondrial Dysfunction Increasing Neuronal Vulnerability to TDP-43 Toxicity | MCU, CK1D, CSNK2A1, GSK3B, PARP1 | 0.470 | $0.47 | SDA-2026-04-07-gap-p |
| #604 | APOE and TREM2 interact to modulate age-dependent microglial dysfunction | TREM2 | 0.467 | $0.50 | aging-mouse-brain-20 |
| #605 | Cross-Tissue Communication Disruption | MULTIPLE | 0.466 | $0.51 | SDA-2026-04-16-gap-b |
| #606 | Microglial Priming Window for HDAC1-Dependent DAM Transition | HDAC1 | 0.463 | $0.46 | SDA-2026-04-07-gap-d |
| #607 | Gamma-Entrained PV Interneurons Enable Precision p-tau217-Guided lncRNA Exosome Therapy in Early-Stage Alzheimer's Disease | PVALB, lncRNA-0021 | 0.461 | $0.00 | SDA-2026-04-16-gap-p |
| #608 | CSF Neurofilament Light Chain-Guided Astrocyte-Derived Extracellular Vesicle Delivery of lncRNA-0021 in AD | CSF neurofilament light chain (NfL), lncRNA-0021, astrocyte-derived extracellular vesicles | 0.461 | $0.46 | SDA-2026-04-16-gap-p |
| #609 | Mitochondrial Dysfunction in Neurodegeneration | NDUFV1 | 0.460 | $0.00 | - |
| #610 | Seed Conformational Heterogeneity Explains Variable Chaperone Susceptibility—Strain-Specific Targeting Required | DNAJC7, PTGDS, tau conformers | 0.460 | $0.46 | SDA-2026-04-06-gap-d |
| #611 | DNMT3A-Mediated de novo Methylation Corrects 'Epigenetic Scars' at Polycomb Targets | DNMT3A | 0.460 | $0.53 | SDA-2026-04-10-gap-2 |
| #612 | CSF Neurofilament Light-Triggered Astrocyte-Derived Exosome Dosing Maximizes lncRNA-0021 Therapeutic Window in AD | CSF neurofilament light (biomarker), lncRNA-0021, astrocyte-derived exosomes | 0.460 | $0.00 | SDA-2026-04-16-gap-p |
| #613 | Selective Microglial Senescence Targeting via TREM2 Modulation | TREM2 | 0.459 | $0.50 | SDA-2026-04-04-gap-s |
| #614 | Selective OGA Inhibition as 'Tau Stabilization' Strategy Without Phosphorylation Cross-Talk | MGEA5 (OGA) | 0.458 | $0.51 | SDA-2026-04-13-gap-d |
| #615 | C1q Inhibition Prevents Synaptic Mitochondrial Dysfunction via Microglial-Neuronal Cross-Talk Normalization | C1QA/C1QB/C1QC | 0.455 | $0.45 | SDA-2026-04-15-gap-p |
| #616 | SREBP-2 Upstream Modulation for APOE4 Lipidation Enhancement | SREBP-2/SCAP | 0.453 | $0.45 | SDA-2026-04-16-gap-d |
| #617 | Metabolic Reprogramming Toward GAPDH Inhibition | GAPDH, HK2 | 0.450 | $0.52 | SDA-2026-04-07-gap-p |
| #618 | Astrocytic APOE4 Disruption of GABAergic Support Increasing Neuronal Vulnerability | SLC1A2 (GLT-1), GABRA1, GABRB3, GAD1 | 0.450 | $0.45 | SDA-2026-04-07-gap-p |
| #619 | α-Ketoglutarate/2-HG Metabolic-Epigenetic Window in Neurons | 2-HG/KDM4B | 0.443 | $0.44 | SDA-2026-04-07-gap-d |
| #620 | RAGE/STAT3/IL-6 Autocrine Loop Mediates Aβ-Induced SPP1 Upregulation in Perivascular Fibroblasts | SPP1 | 0.442 | $0.44 | SDA-2026-04-06-gap-p |
| #621 | Test: TREM2 enhances amyloid clearance | - | 0.437 | $0.44 | - |
| #622 | Blood-Brain Barrier Disruption Enabling Peripheral Inflammatory Insult | PDGFRB, CLDN5, OCLN, FGB | 0.430 | $0.43 | SDA-2026-04-07-gap-p |
| #623 | DNA Damage Repair Dysfunction Creating TDP-43 Pathology Feed-Forward Loop | PARP1, ATM, XRCC1, LIG3 | 0.430 | $0.43 | SDA-2026-04-07-gap-p |
| #624 | GSK3β Inhibition to Prevent α-Synuclein Phosphorylation and Aggregation | - | 0.429 | $0.43 | SDA-2026-04-17-gap-p |
| #625 | C1q-Targeted miR-33 ASO Delivery for APOE4 Hyper-Lipidation via Microglial Receptor-Mediated Transcytosis | miR-33a/miR-33b | 0.427 | $0.00 | SDA-2026-04-16-gap-d |
| #626 | P2X7/P2Y12 Purinergic Signaling Connects Aβ Aggregation to SPP1 Transcription via Calcineurin/NFAT Pathway | SPP1 | 0.423 | $0.63 | SDA-2026-04-06-gap-p |
| #627 | C1q-Conjugated miR-33 ASO Brain Delivery for Enhanced APOE4 Lipidation | miR-33a/miR-33b | 0.423 | $0.00 | SDA-2026-04-16-gap-d |
| #628 | IGFBPL1 Peptide Mimetics for Drug-Like BBB Permeability | IGFBPL1 | 0.420 | $0.66 | SDA-2026-04-06-gap-d |
| #629 | P2RY12-mediated cerebral VSMC dysfunction establishes a vicious cycle with microglial P2RY12 activation | P2RY12 (dual: VSMC + microglia) | 0.418 | $0.42 | SDA-2026-04-07-gap-p |
| #630 | HDAC2-Specific Repression of PU.1 Pioneer Factor Target Sites Suppresses the IL-33/ST2-Phagocytic Axis; HDAC2 Deletion Specifically Unmasks These Enhancers | HDAC2 | 0.415 | $0.46 | SDA-2026-04-13-gap-p |
| #631 | CK2-mediated HSP90α phosphorylation switches client discrimination toward disease conformers | HSP90AA1, CSNK2A1, CSNK2A2 | 0.410 | $0.41 | SDA-2026-04-10-gap-d |
| #632 | Test: TREM2 enhances amyloid clearance | - | 0.405 | $0.41 | - |
| #633 | Test: TREM2 enhances amyloid clearance | - | 0.400 | $0.41 | - |
| #634 | Test: TREM2 enhances amyloid clearance | - | 0.400 | $0.41 | - |
| #635 | Test: TREM2 enhances amyloid clearance | - | 0.400 | $0.41 | - |
| #636 | Test: TREM2 enhances amyloid clearance | - | 0.400 | $0.41 | - |
| #637 | Test: TREM2 enhances amyloid clearance | - | 0.400 | $0.40 | - |
| #638 | Age-driven synaptic gene silencing precedes neuronal loss in vulnerable brain regions | SYP | 0.390 | $0.50 | aging-mouse-brain-20 |
| #639 | LRP1-Autophagy BBB Permeabilization for Antibody Transport | LRP1; ATG7; OPTN (autophagy pathway); CLDN5 (tight junctions) | 0.380 | $0.38 | SDA-2026-04-02-gap-b |
| #640 | Hippocampal mitochondrial dysfunction accelerates with age and drives regional AD vulnerability | TFAM | 0.374 | $0.50 | aging-mouse-brain-20 |
| #641 | P2RY12 activation induces cellular senescence in cerebral VSMCs, driving neurodegeneration via SASP secretion | P2RY12 | 0.373 | $0.37 | SDA-2026-04-07-gap-p |
| #642 | Age-related neuroinflammation mimics early Alzheimer's disease pathology | GFAP | 0.362 | $0.50 | aging-mouse-brain-20 |
| #643 | Direct APOE4-TDP-43 Protein-Protein Interaction Promoting Aggregation Seeding | APOE, TARDBP | 0.360 | $0.39 | SDA-2026-04-07-gap-p |
| #644 | Novel Hypothesis on Metabolic Dysregulation in Neurodegeneration | SLC16A1 (MCT1) | 0.330 | $0.39 | - |
| #645 | CHMP2B vs. CHMP2A Subunit Targeting Creates a Therapeutic Window in ESCRT-Dependent Tau Sorting | CHMP2B, CHMP2A, CHMP4B | 0.330 | $0.33 | SDA-2026-04-06-gap-d |
| #646 | [Archived Hypothesis] | - | 0.300 | $0.30 | - |
| #647 | [Archived Hypothesis] | - | 0.300 | $0.30 | - |
| #648 | IL-33/ST2 Axis Augmentation for Synaptic Protection | - | 0.105 | $0.20 | SDA-NEUROINFLAM-BIOM |
| #649 | P2RX7-PANX1 Channel Blockade for Neuroinflammatory Cascade Interruption | - | 0.105 | $0.20 | SDA-NEUROINFLAM-BIOM |
| #650 | TYROBP Causal Network Inhibition for Microglial Repolarization | - | 0.105 | $0.20 | SDA-NEUROINFLAM-BIOM |